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Abstract

Joseph N. Capilato
SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL QUORUM SENSING
COMPOUNDS
2015-2016
Lark J. Perez, Ph.D
Master of Science in Pharmaceutical Science

Bacteria communicate with chemical signals in a process known as quorum
sensing. This population density-dependent process involves the bacterial production,
release and detection of structurally specific small molecules and enables the bacterial
pathogen to regulate its virulence on a population-wide level. Using a variety of chemical
and biological techniques, I have studied various quorum sensing systems in several
bacteria, including Vibrio cholera and Pseudomonas aeruginosa. A key principle of this
research involves the design, synthesis and testing of novel compounds for their
biological activity. These molecules are typically based off of an initial lead target, which
is often identified from a high-throughput screen and serves as a template for further
optimization. Specifically, I have researched quorum sensing compounds that affect HfqRNA interactions in V. cholera, the LasR receptor in P. aeuruginosa and HapR in V.
cholera. Taken together, the results of these studies provide a basis for future
investigations involving quorum sensing, and demonstrate how organic chemistry can be
employed to study these fascinating biochemical systems.

v

Table of Contents
Abstract ............................................................................................................................v
List of Figures ..................................................................................................................vii
List of Tables ...................................................................................................................viii
Chapter 1: Design of Small Molecule Inhibitors of a Protein-RNA Interaction in
Vibrio Cholera .................................................................................................................1
Introduction ................................................................................................................1
Results and Discussion ..............................................................................................2
The Dose-Response Relationship for Compound 1 is a Bell Curve ...................2
An Aminal is Required for Biological Activity ..................................................3
Development of Truncated Analogs Establishes the Unimportance of the
Aryl Sulfonamide Moiety ...................................................................................4
Development of Oxazolidinone Derivatives Addresses Issue of Stability
and Toxicity........................................................................................................6
Identification of a Higher Potency Compound...................................................7
Chemistry ...................................................................................................................8
Conclusion .................................................................................................................12
Experimental Section .................................................................................................20
Bacterial Reporter Strain Assay .........................................................................20
General Chemistry..............................................................................................20
Chapter 2: Development of Photolabile Protecting Groups for a Bioactive
Compound ........................................................................................................................60
Introduction ................................................................................................................60
Results and Discussion ..............................................................................................61
Development of the HapR-Riboswitch Construct ..............................................61
vi

Table of Contents (continued)
Analysis of NPOM-Caged Theophylline ...........................................................62
Discovery and Evaluation of new Photocages ...................................................63
Chemistry ...................................................................................................................64
Conclusion .................................................................................................................65
Experimental Section .................................................................................................66
General Chemistry..............................................................................................66
Chapter 3: Gem-Dinitro Enols: Discovery and Application of a new Reaction for
Methyl Ketones ................................................................................................................80
Introduction ................................................................................................................80
Results and Discussion ..............................................................................................81
Isolation of Key Intermediates Leads to the Elucidation of the Reaction
Mechanism .........................................................................................................81
Nucleophile Substrate Scope is Wide-Ranging..................................................83
Ketone Substrate Scope Includes Both Aromatic and Alkyl Methyl Ketones...84
Application of This new Reaction to Produce Medicinally Relevant
Compounds.........................................................................................................86
Conclusion .................................................................................................................87
Experimental Section .................................................................................................89
General Chemistry..............................................................................................89
Chapter 4: Structure-Activity Relationship of a Triphenyl Scaffold for the LasR
Receptor in Pseudomonas Aeruginosa ............................................................................106
Introduction ................................................................................................................106
Results and Discussion ..............................................................................................110
Synthesis .............................................................................................................110
"A-Ring" Structure Activity Relationship Studies .............................................111
vii

Table of Contents (continued)
"C-Ring" Structure Activity Relationship Series ...............................................112
Conclusion .................................................................................................................120
Experimental Section .................................................................................................121
Bacterial Reporter Strain Assay .........................................................................121
General Chemistry..............................................................................................121
Chapter 5: Reduction of Virulence in P. Aeruginosa Through Quorum Sensing
Inhibition by Lipoxin A4 ..................................................................................................190
Introduction ................................................................................................................190
Results ........................................................................................................................193
Blood Bacterial Load..........................................................................................193
Neutrophil Apoptosis and Free Radical Production ...........................................193
Neutrophil Phagocytic Ability and CD64 Expression .......................................193
Inhibition of Pyocyanin Expression by LXA4 ....................................................195
Inhibition of LasR QS by LXA4 .........................................................................196
Discussion ..................................................................................................................199
Experimental Section .................................................................................................202
Conclusion .................................................................................................................208
References ........................................................................................................................211

viii

List of Figures
Figure

Page

Figure 1. Structure of HTS (1) and examples of some analogs prepared ........................14
Figure 2. Dose response curve for 1 ................................................................................14
Figure 3. Analogs developed using stable linkers ...........................................................15
Figure 4. Dose response curve for 2 ................................................................................15
Figure 5. OD600 plot for 1 and 2 .......................................................................................16
Figure 6. Biological activity of three truncated analogs ..................................................16
Figure 7. Dose response curve for the oxazolidinone analog ..........................................17
Figure 8. OD600 plot for the oxazolidinone analog...........................................................17
Figure 9. Dose response curve for 4 ................................................................................18
Figure 10. Methods employed for the synthesis of 2-substituted benzimidazoles ..........18
Figure 11. Synthesis of acetal intermediates....................................................................19
Figure 12. Various methods utilized to form N, N-acetals ..............................................19
Figure 13. TheoRS-hapR-mKate construct in V.c ...........................................................74
Figure 14. Photolysis of new nitrile photocage ...............................................................74
Figure 15. Photolysis of big-PEG analog ........................................................................75
Figure 16. Synthesis of caged-theophylline .....................................................................75
Figure 17. Reaction scheme and examples of nucleophile substrate scope .....................88
Figure 18. Proposed reaction mechanism ........................................................................88
Figure 19. Crystal structure and synthetic details ............................................................108
Figure 20. Effect of amide bond configuration and identification of potent LasR
antagonists .......................................................................................................................118
Figure 21. Hybrid analogs containing optimized structural features ...............................118
ix

List of Figures (continued)
Figure 22. LXA4 inhibits the expression of P. aeurignosa virulence factor,
pyocyanin .........................................................................................................................209
Figure 23. LXA4 inhibits the LasR QS receptor ..............................................................209
Figure 24. Competition binding assay for LXA4 inhibition of LasR ...............................210

x

List of Tables
Table

Page

Table 1. Structure-activity relationship of “A-ring” analogs ...........................................116
Table 2. Structure-activity relationship of “C-ring” ........................................................117
Table 3. Structure-activity relationship of alternative linkers .........................................118
Table 4. Chloropyridine analogs as antagonists of LasR .................................................118

xi

Chapter 1
Design of small molecule inhibitors of a protein-RNA interaction in Vibrio
cholera
Introduction
Protein-RNA interactions facilitate various biochemical processes that are
fundamental for life1,2,3. Chief among these is the translation of proteins, in which gene
expression can be regulated by a specific protein-RNA interaction2,3. In theory, many of
these protein-RNA complexes should represent a potential target for medicinal chemists,
as the ability to modulate gene expression is scientifically and medically useful. For that
reason, it is surprising how few drugs that are currently on the market take advantage of
this untapped interaction. The ability to discover small molecules that interact specifically
with protein-RNA complexes is of growing interest and while not entirely trouble-free,
has been shown to be at the very least, possible.
Recently, my collaborator Prof. Ng at Tufts University developed an assay to
identify inhibitors of a specific protein-RNA interaction in V. cholera. Using highthroughput screening, Prog. Ng tested a library of small molecules and found several hit
compounds that inhibit a protein-RNA complex of the protein Hfq. This widely
conserved bacterial protein mediates the expression of important quorum sensing proteins
through the binding of sRNAs known as the Qrrs2,3,4. In V. cholera, Hfq bound to sRNAs
known as the Qrrs results in destabilization of the quorum sensing master regulator,
HapR2. As HapR normally functions to suppress virulence, the inhibitory action of the
Hfq- Qrr complex on HapR serves to upregulate virulence2. El-Mowafi et al. published a
paper in 2014 on inhibitors of Hfq-RNA interactions, and was the only relevant precedent
that could be found on this topic1. The active compounds from their study, however, were
1

cyclic peptides rather than small molecules, which benefit from enhanced pharmaceutical
properties such as solubility and permeability1. In fact, the authors mentioned in the
discussion section that a small molecule that binds to the site of RI20, their lead peptide,
would be a "candidate anti-infective"1. They go on to mention that the compounds could
be rationally designed once the crystal structure of the Hfq complex is known, or they
could be discovered via high-throughput screening1. Having identified a small molecule
that inhibits one of these particular protein-RNA interactions, Hfq is now a viable target
to reduce bacterial virulence. After synthesizing and retesting the original hit compound
1, I prepared a library of analogs and ultimately identified a derivative with significantly
improved efficacy and reduced toxicity.
Results and Discussion
The dose-response relationship for Compound 1 is a bell curve. During the
early attempts to test the biological activity of compound 1, the maximum concentration
tested was 100 µM. The dose-response curves for these trials appeared to have a
sigmoidal shape, increasing in magnitude up to 100 µM, and therefore, it was
hypothesized that these curves would flatten out in a sigmoidal fashion if higher
concentrations were tested. Upon performing another assay that included concentrations
up to 300 µM, it was discovered that the dose-response relationship was not sigmoidal,
but was actually a bell curve (or an inverted-U) (Fig. 2). For compound 1, before 100 µM
seems to be the optimal concentration in which the highest response level is reached,
while concentrations higher than 100 µM are in the decline section of the bell curve (Fig.
2). To explain this phenomenon we looked at the luminescence and OD600 data
separately, each plotted as a dose-response. From the OD600 plot (Fig. 5) it is apparent
2

that there is some growth inhibition at concentrations leading up to 100 µM, and the low
OD600 values for concentrations higher than 100 µM suggest that those cells are dead.
While it was discouraging to learn of this problem with toxicity at high concentrations,
this was a critical observation that helped explain the unique dose-response relationship
for compound 1. Other analogs that were synthesized and tested all repeated this bell
curve effect, and accordingly also suffered from growth inhibition at high concentrations
(some to a lesser extent, however).
An aminal is required for biological activity. After becoming aware of how
significantly instable the N, N-acetal truly was, a series of experiments were performed to
test if the aminal was actually necessary for activity. Firstly, the breakdown products
from the hydrolysis of the aminal, the free benzimidazole and piperazine portions, were
tested individually in the assay along with 1. Neither of these fragments produced a
significant response compared to 1, and therefore it was concluded that the coupled
molecule is required for activity. However, while this assay supported the notion that the
coupled benzimidazole-piperazine compound is required, it was still uncertain whether
those portions needed to be coupled via the N, N-acetal. To test this, three new analogs
were designed and synthesized, which utilized different linkers to couple the two portions
of the molecule (Fig. 3). The first of these compounds is identical to 1, but with a
carbonyl on the carbon involved in the aminal, resulting in a urea-type analog. This
change has a negligible effect on the molecule's properties such as size, but the
compound now becomes significantly more stable, no longer containing the acid-labile
aminal. Similarly, two other new analogs of 1 were prepared, one that utilizes a
sulfonamide linker, and another that contains a two-carbon linker (Fig. 3). These three
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linker-derivatives were tested against 1 in the assay, and surprisingly none of them
produced any measurable level of activity. Ultimately, these experiments taken together
leads us to a somewhat paradoxical notion, that the coupled benzimidazole-piperazine
molecule is required for activity but these two portions must be linked together via an N,
N-acetal. Since the aminal is known to readily hydrolyze even under mild conditions, it is
peculiar that this functional group would behave as a pharmacophore. One possible
explanation is that the coupled aminal is not actually the active compound, but rather a
pro-drug, which during hydrolysis generates reactive intermediates that function as the
true biologically active species. Concluding that we could not avoid incorporating the
aminal into the structure, we focused our attention on developing methods to synthesize,
purify and handle theses sensitive molecules as best as possible.
Development of truncated analogs establishes the unimportance of the aryl
sulfonamide moiety. The initial SAR (structure-activity relationship) we obtained
informed us that changes to the benzyl group of the benzimidazole were not tolerated.
Analogs that were prepared and tested modified the benzyl to phenyl, cyclohexyl,
pyridine, ortho-methoxybenzyl or para-bromobenzyl (Fig. 1). Of this small series, every
compound was inactive with the exception of the pyridine analog, for which a response
was observed that was negligible compared to 1. After this result, our strategy for
rationale design of derivatives shifted to modifications of the cyanobenzene group. Being
limited to the few aryl sulfonyl chlorides we had available, four analogs that made
changes to this ring were synthesized and tested (Fig. 1). While all of these molecules
were active in our assay, none of them were more efficacious than 1, although the orthonitro derivative produced the most comparable response. Most interesting was the result
that not just small changes (i.e. ortho-nitro) were tolerated but also substantial alterations
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(i.e. para-methyl, trichloro, pentafluoro) did not cause a loss in activity. The latter
observation caused another reassessment of our synthetic rationale, as the importance of
this cyanobenzene group was uncertain. To address this, an analog was designed which
removed the aryl sulfanamide group entirely, changing the secondary amine involved in
the N, N-acetal from the substituted piperazine to morpholine (2). Unexpectedly, this
compound was not only active but was equally as potent and slightly more efficacious
than 1 at the third highest concentration (Fig. 4). Building off this result, a couple more
truncated analogs were prepared and tested in addition to the morpholine derivative,
incorporating piperidine, N-methylpiperazine, and dimethylmorpholine into the aminal
(Fig. 1). These compounds were also active but did not match the response level of 2
(Fig. 6). Unfortunately, the truncated series also suffered from growth inhibition at the
same concentrations as 1, although slightly higher OD600 values were recorded for the
morpholine analog than for 1 (Fig. 5). Even though the toxicity issue still persisted, the
fact that these four compounds maintained (and in one case, somewhat improved) activity
after a large part of the molecular structure was removed was remarkable. Furthermore,
the chemical properties of these new analogs are superior to 1 in regards to making the
compound more drug-like. The truncated analogs are not only smaller molecules but also
are more hydrophilic; for instance comparing 1 to 2, the molecular weight has been
reduced from 472 to 323 g/mol and the cLogP value decreased from 4.85 to 3.60. Given
the critical SAR that was provided by this series, subsequent analogs did not contain the
sulfonamide cyanobenzene moiety.
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Development of oxazolidinone derivatives addresses issue of stability and
toxicity. Having experimented thoroughly with analogs based off of piperazine, an
interest developed in testing N, N-acetals of other NH heterocycles. Attempts to form the
aminal from the benzimidazole failed for pyrrole, imidazole, succinimide, tetrazole and
several other substrates. Oxazolidinone, on the other hand, was identified to be capable of
forming the aminal with benzimidazole, and the product could be isolated in an aqueous
workup just as the piperazine-based analogs. Upon testing this new derivative, the
somewhat impure sample produced promising data, reaching a higher Lux/OD600 value
than 1. This preliminary result led to the development of several other oxazolidinonebased analogs. Several substituted oxazolidinones (isopropyl, phenyl and benzyl) were
purchased relatively inexpensively, due to their common use as Evans chiral auxiliaries.
Forming the aminal proceeded smoothly with these new substrates, as well as the
unsubstituted oxazolidinone, and the coupled product seemed to be a bit more robust than
the piperazine-based aminals such as 1. The enhanced stability of these derivatives was
confirmed via the identification of a purification method that did not hydrolyze the
aminal. Using alumina instead of silica, the oxazolidinone-based N, N-acetals could be
purified, whereas the piperazine-based aminals hydrolyze on both alumina and silica.
This change in stability is thought to be due to the decreased basicity of the nitrogen of
the oxazolidinone, compared to the nitrogen in piperazine which protonates much more
readily, thereby initiating the mechanism for hydrolysis of the aminal. Upon testing these
more stable analogs it was interesting to see that they experienced significantly reduced
growth inhibition at high concentrations in comparison to 1 (Fig. 8). This result supported
our initial hypothesis that the instability/reactivity of the N, N-acetal was the cause for
the toxicity issue. In regards to the biological response, surprisingly the unsubstituted
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oxazolidinone analog was no longer active in its pure form. The other derivatives,
however, were active, chief among them being the benzyl-substituted oxazolidinone
analog (3). Shockingly, this analog produced a drastically higher level of efficacy than 1,
having almost quadrupled the maximum Lux/OD600 value of 1 (Fig. 7). Perhaps even
more important, though, was the decreased toxicity of this new analog. The OD600 plot of
3 depicts no substantial growth inhibition at the three highest concentrations tested,
whereas 1 is shown to have decreasing cell density starting at the third highest
concentration, and the cells appear to be completely dead by the final two concentrations
(Fig. 8). Taking these results together, this oxazolidinone derivative has addressed issues
with stability, toxicity and efficacy, and thus has provided a stronger basis for ongoing
SAR efforts.
Identification of a higher potency compound. Up to this point in the project,
several parameters of 1 had been optimized, including efficacy, toxicity, stability,
solubility and molecular weight. Achieving potency that was superior to 1, however, was
difficult and every analog that was tested had either the same potency as 1 or slightly
worse. A new compound that I proposed aimed to address this concern by incorporating
more than one aminal into the structure - as this reactive functional group was found to be
vital for activity. Many potential approaches could be used to introduce an additional N,
N-acetal into the structure of 1; however, the compound that was designed and ultimately
synthesized was perhaps the most straightforward. By employing piperazine rather than
morpholine or another mono-NH heterocycle, two N, N-acetals can be formed, resulting
in a symmetrical molecule. This product was isolated in relatively high yield but could
not be purified using alumina to remove the excess benzimidazole, and consequently was
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used without purification in the assay. Excitingly, this analog did in fact have increased
potency compared to 1 (Fig. 9). At around 10 µM 1 produces essentially no response
(less than 1,000 Lux/OD600), whereas this new analog was found to be fairly effective at
this concentration, having a Lux/OD600 value of around 12,000. While a greater increase
in potency can likely still be obtained, this was a significant breakthrough as it was the
first and only compound in the library to improve upon the potency of 1.
Chemistry
Although initially assumed to be relatively straightforward, synthesizing the highthroughput hit proved to be a complicated task. Retrosynthetically, the desired molecule
is the coupled product of two different secondary amines linked via a methylene group,
which originates from formaldehyde. The resulting N, N-acetal (or aminal) proved to be a
major synthetic difficulty due to its acid lability, the degree of which was not initially
understood until attempting to make these molecules. After many unsuccessful attempts
to synthesize the high-throughput screen hit, it was assumed that the Mannich reaction
that forms that aminal was not occurring for these substrates. To our surprise, it was
discovered that the aminal was indeed forming, however was being fully hydrolyzed
during the purification, thus regenerating the two starting materials. This observation was
the first indication that these molecules were not particularly stable, since the stationaryphase used during the purifications (silica) is only very slightly acidic. While no universal
solution was found to solve this problem of stability, several techniques were identified
and developed to make it possible to work with this highly acid-labile functionality.
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While forming the N, N-acetal to access the final compound was rather
problematic, the prior reactions that form the necessary amines proceeded fairly well. The
high-throughput screen hit was retrosynthetically split into two halves, a benzimidizole
and a piperazine portion. These are both commonly synthesized heterocycles that are
employed throughout medicinal chemistry, and for that reason, various methods were
effectively identified to prepare them. The required substituted benzimidazole, 2-benzyl1H-benzimidazol, was synthesized from ortho-phenylenediamine and phenylacetic acid
(Fig. 10). Several methods were explored to facilitate this condensation reaction, each
using a different reagent to activate the carboxylic acid for nucleophilic attack. Initially
BH3 was used, in which the borate ester was formed and ultimately gave the desired
product in decent yield. Alternatively, borane could be avoided by using a more common
coupling reagent, like EDC, but this method was not preferred due to the fact that the
monoamide intermediate had to be isolated as opposed to the one-pot approach using
borane. A third method to form the benzimidazole that was investigated involved
polyphosphoric acid, which was also a one-pot reaction7. This became the main
approach, as it typically gave high yield and purity without any purification. Its only
downside, being a potentially troublesome workup, is what led to the continued use of the
other methods described. Typically, forming the benzimidazole was first attempted using
polyphosphoirc acid, and if the product was not isolated then the other methods were
employed. Synthesizing the piperazine portion of the molecule was a bit simpler; the
reaction between the various substituted aryl sulfonyl chlorides and excess piperazine
proceeded very well (Fig. 11). The desired mono-sulfonamide piperazine derivatives
were isolated in extremely high yield and purity via an aqueous workup.
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My initial efforts to form the aminal were carried out using common Mannich
reaction conditions (Fig. 12, A). The reactions were usually done in methanol at room
temperature and formalin was used as the formaldehyde source (37% in water). Two
methods were explored in regards to addition of the secondary amines, one in which both
are added simultaneously and another where the benzimidazole is added after the
piperazine portion reacts with formaldehyde for a short period of time. Using either
method, the material was purified using silica-gel flash chromatography after a normal
workup, but the product was never isolated. We originally speculated that the aminal was
not in fact forming due to the consistent isolation of the benzimidazole starting material.
It wasn't until after numerous failed attempts to purify the compound that a crude H1
NMR was assessed. Surprisingly, it appeared that the aminal was forming as the
characteristic methylene peak around 5-6 ppm was present, but since we did not observe
this peak after purification it was concluded that the molecule was hydrolyzing on silica.
While I did not have a solution for this problem at the time, it was reassuring to discover
that the reaction was truly working on these substrates.
After experimenting with those basic Mannich conditions for a while, I began
researching new ways of forming N, N-acetals. My initial goals were to optimize the
reaction in regard to yield and purity, and potentially identify a highly efficient procedure
in which product could be isolated that did not need to be purified. Using SciFinder's
Reaction Structure search, several interesting papers were found which detailed novel
methods of forming aminals. The first paper we focused on, a paper published in 2010 in
Journal of Organic Chemistry, described a method to access aminals via N, O-acetals.
The secondary amine (piperazine) is reacted with paraformaldehyde and potassium
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carbonate in methanol to generate the corresponding N, O-acetal (Fig. 11). This
intermediate is then reacted with a NH heterocycle (benzimidazole in this case) in the
presence of hafnium triflate to form the N, N-acetal (Fig. 12, B). According to the paper,
if using indole instead of benzimidazole as the NH heterocycle, then using hafnium
triflate as a Lewis acid catalyst regioselectively produces aminals whereas TMSCl
generates 3-aminomethylated indoles. In the case of 2-benzyl-benzimidazole, the
hafnium triflate conditions did produce the desired product in 64% yield. This marked the
first time we isolated the aminal product and while it was exciting to learn that these
compounds were at least stable enough to isolate, we still desired to optimize the
conditions to improve yield and potency.
The next method to synthesize N, N-acetals that we explored was based off of
another Journal of Organic Chemistry paper which was published in 2006. The authors
described a route to form aminals between secondary amines and NH heterocycles by
first forming a bis-aminal of the secondary amine. This is accomplished by reacting two
molar equivalence of the amine with 1 eq. of formaldehyde (as formalin) and then
extracting the bis-aminal in an aqueous workup (Fig. 11). Subsequent reaction of this bisaminal with an NH heterocycle in the presence of succinic anhydride provides the desired
N, N-acetal (Fig. 12, C). In my attempts using this method, forming the bis-aminal
worked well for simple secondary amines (piperazine-based) but not for many other
amines that were tested. However, if I was able to produce the bis-aminal then the
following step which forms the desired aminal always worked in my experience.
Importantly, these conditions produced higher yield and purity than the N, O-acetal
method, and in some cases the product did not require any further purification. The
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limitation to only piperazine-based secondary amines, however, is what led us to further
explore alternatives to forming these aminals.
A fourth method to prepare relevant N, N-acetals was focused on using
chloroaminals as intermediates and therefore accessing the desired aminals via an SN2
reaction. An efficient procedure was identified from a Tetrohedron Letters paper in which
a secondary amine is reacted with paraformaldehyde in TMSCl to generate the
chloroaminal (Fig. 11). An NH heterocycle is then deprotanated via NaH before the
chloroaminal intermiediate is introduced to the reaction, which rapidly affords the N, Nacetal (Fig. 12, D). This preparation did not work with every substrate that were tested, as
some of the amines did not readily form the chloroaminal. Nevertheless, several
secondary amines could be converted to the chloroaminal and then the corresponding N,
N-acetal product. Notable among these amines was the oxazolidinone class of
heterocycles, which seemed to form N, Cl- and the N, N- acetals with high efficiency.
Taking the results of all the aminal-forming methods together, it seems to be very
substrate dependent, wherein a given NH substrate (piperazine vs. oxazolidinone) may
favor one of the methods over another, or may work for one method but not for another.
Luckily, many of the compounds I set out to make were in fact possible to synthesize
using one of the methods described here.
Conclusion
Development of small molecule inhibitors of protein-RNA interactions is a
difficult task, even when the active compounds are stable. In this study, a series of
structurally related N, N-acetals were synthesized and tested for their biological activity.
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Structure-activity relationships were determined for the various groups that constitute the
target molecule, but ultimately most structural changes caused either a complete loss of
activity or a level of activity comparable to the high-throughput screen hit. After many
failed attempts, several analogs finally improved upon compound 1 by increasing
efficacy, stability, potency and/or decreasing toxicity. Several advances were also made
in regards to the synthesis of these compounds. Working with molecules containing
unstable aminals presented a learning curve and therefore significant time was dedicated
to studying various methods to forming and isolating compounds containing these
groups. Eventually, several efficient synthetic approaches to form N, N-acetals were
identified and adapted for our substrates, which is what enabled the production of a
diverse compound library. In regards to medicinal impact, this project supports the notion
that Hfq is a novel target to inhibit bacterial virulence. While more work needs to be done
regarding Hfq and specifically Hfq-Qrr complexes, the wide range of activities that were
observed throughout this compound library provides promise for future efforts of
"drugging" this target. The work described here provides a basis for other projects
involving small molecule inhibitors of protein-RNA interactions as well as others in
which the lead compound contains an N, N-acetal. This project is currently being
prepared for publication, as our collaborators are performing the last studies to identify
the mechanism of action.
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Figure 1. Structure of HTS hit (1) and examples of some analogs prepared

Figure 2. Dose response curve for 1
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Figure 3. Analogs developed using stable linkers

1
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Figure 4. Dose response curve for 2
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Figure 5. OD600 plot for 1 and 2

(2)

Figure 6. Biological activity of three truncated analogs
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Figure 7. Dose response curve for high-efficacy oxazolidinone analog
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Figure 8. OD600 plot of oxazolidinone analog
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1
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Figure 9. Dose-response curve for 4

Figure 10. Methods employed for the synthesis of 2-substituted benzimidazoles
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Figure 11. Synthesis of acetal intermediates

Figure 12. Various methods utilized to form N, N-acetals
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Experimental Section
Bacterial reporter strain assay. Our collaborator Prof. Ng developed the
biological assay for this project. A reporter strain was first produced using V. cholera in
which the expression of a luminescent protein is controlled by Hfq-sRNA. For practical
purposes, an increase in luminescence (or Lux/OD600) corresponds to an increase in
inhibition of the Hfq-Qrr complex, whereas compounds that do not effect this proteinRNA interaction do not generate luminescence. To prepare for the assay, an overnight
culture of the V. cholera reporter strain was incubated at 30 °C in LB media containing
100 µg/mL of Kanamycin and 5 µg/mL of Tetracyclin. Following a 1:50 dilution of this
culture into the same LB media, 175 µL was placed into each well of a clear bottom 96well plate. Next, 10.5 µL of a 10 mM solution of each compound in DMSO was added in
triplicate to the wells in the first column. A 2.4 fold dilution was then performed by
transferring 125 µL from the first column to the next, and repeating this down the entire
plate. Plates were incubated at 30 °C and luminescence (Lux) and OD600 were read at 4, 5
and 6 hours. Dose response curves were generated using Prism software, and were
plotted as Lux/OD600 vs. log[conc.].
General chemistry. All reagents and solvents were obtained from commercial
sources and used without further purification or drying. Reactions were performed under
a nitrogen gas atmosphere in flame-dried glassware. Unless otherwise noted, compounds
were not purified. 1H and 13C NMR data was taken on a Varian AS400 (400 MHz), with
chemical shifts being displayed in a ppm scale referenced to residual chloroform.
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2-benzyl-1H-benzo[d]imidazole. Orthophenyllene diamine (1 g, 9.25 mmol) and
phenyl acetic acid (1.25 g, 9.25 mmol) was added to poly phosphoric acid (4.4 mL, 1
g/mmol) and the mixture was heated to 180 °C for 12 h. NaOH (1 M, 15 mL x 3) was
added, after the flask was saturated with sand (while hot). Combined NaOH portions
were neutralized with 1 M HCl, and the resulting aqueous solution was extracted with
EtOAc (3 x 50 mL). Combined organic layers were washed with brine and dried with
Na2SO4 to afford 1.77 g, 92% yield. NMR spectra are consistent with previously
published data.
2-phenyl-1H-benzo[d]imidazole. Prepared using the procedure described for 2benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid. NMR spectra are
consistent with previously published data.
2-(cyclohexylmethyl)-1H-benzo[d]imidazole. Prepared using the procedure
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid.
NMR spectra are consistent with previously published data.
2-(2-methoxybenzyl)-1H-benzo[d]imidazole. Prepared using the procedure
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid.
NMR spectra are consistent with previously published data.
2-(pyridin-3-ylmethyl)-1H-benzo[d]imidazole. Prepared using the procedure
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid.
NMR spectra are consistent with previously published data.
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2-(4-bromobenzyl)-1H-benzo[d]imidazole. Prepared using the procedure
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid.
NMR spectra are consistent with previously published data.
2-((2,4-dichlorophenoxy)methyl)-1H-benzo[d]imidazole. Prepared using the
procedure described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding
carboxylic acid. 1H NMR (400 MHz, CDCl3) δ 9.94 (s, 1H), 7.75 (s, 1H), 7.50 (s, 1H),
7.39 (dd, J = 2.5, 0.5 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.18 (dd, 1H), 7.01 – 6.96 (m, 1H),
5.43 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 152.14, 149.16, 130.37, 128.15, 127.49,
123.94, 114.94, 65.83.

2-(benzylthio)-5-methoxy-1H-benzo[d]imidazole. Prepared using the procedure
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid.
NMR spectra are consistent with previously published data.
2-benzyl-4-nitro-1H-benzo[d]imidazole. Prepared using the procedure described
for 2-benzyl-1H-benzo[d]imidazole, using the corresponding diamine. NMR spectra are
consistent with previously published data.
2-benzyl-1H-imidazo[4,5-c]pyridine. Prepared using the procedure described for
2-benzyl-1H-benzo[d]imidazole, using the corresponding diamine. NMR spectra are
consistent with previously published data.
8-benzyl-9H-purine. Prepared using the procedure described for 2-benzyl-1Hbenzo[d]imidazole, using the corresponding diamine. NMR spectra are consistent with
previously published data.
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2-benzyl-5,6-dichloro-1H-benzo[d]imidazole. Prepared using the procedure
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding diamine. 1H
NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 7.50 (s, 2H), 7.28 – 7.20 (m, 3H), 7.19 – 7.12
(m, 2H), 4.16 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 155.96, 137.67, 135.59, 129.20,
129.00, 127.66, 126.63, 116.11, 35.67.
2-(piperazin-1-ylsulfonyl)benzonitrile. 2-cyanobenzene sulfonyl chloride (0.5 g,
2.48 mmol) was added to piperazine (1.07 g, 12.4 mmol) in DCM (24 mL, 0.1 M) at 0
°C. Reaction stirred for 30 min at 0 °C and was quenched with sat. NaHCO3 (25 mL).
The mixture was diluted with DCM (25 mL) and separated, and the organic layer was
washed with brine (25 mL) and then dried with Na2SO4. The product was used without
purification, 0.59 g, 96% yield.
1-((2-nitrophenyl)sulfonyl)piperazine. Prepared using the procedure described
for 2-(piperazin-1-ylsulfonyl)benzonitrile, using the corresponding sulfonyl chloride.
NMR spectra are consistent with previously published data.
1-tosylpiperazine. Prepared using the procedure described for 2-(piperazin-1ylsulfonyl)benzonitrile, using the corresponding sulfonyl chloride. NMR spectra are
consistent with previously published data.
1-((2,4,6-trichlorophenyl)sulfonyl)piperazine. Prepared using the procedure
described for 2-(piperazin-1-ylsulfonyl)benzonitrile, using the corresponding sulfonyl
chloride. NMR spectra are consistent with previously published data.
2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile. Paraformaldehyde
(2.12 g, 8.82 mmol) was added to a mixture of 2-(piperazin-1-ylsulfonyl)benzonitrile
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(1.11 g, 4.41 mmol), K2CO3 (1.22 g, 8.82 mmol) and Na2SO4 (1.25 g, 8.82 mmol) in
methanol (14.7 mL, 0.3 M). The mixture stirred at room temperature overnight, and then
was filtered and washed with ether. Removal of solvent in vacuo yielded 1.16 g of the N,
O-acetal, 89% yield. This intermediate was used crude in the next step.
1-(methoxymethyl)-4-((2-nitrophenyl)sulfonyl)piperazine. Prepared using the
procedure described for 2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile,
using the corresponding piperazine derivative.
1-(methoxymethyl)-4-tosylpiperazine. Prepared using the procedure described
for 2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile, using the corresponding
piperazine derivative.
1-(methoxymethyl)-4-((2,4,6-trichlorophenyl)sulfonyl)piperazine. Prepared
using the procedure described for 2-((4-(methoxymethyl)piperazin-1yl)sulfonyl)benzonitrile, using the corresponding piperazine derivative.
Dimorpholinomethane. Morpholine (2.0 g, 22.96 mmol) was added to formalin
(0.86 mL, 11.48 mmol) at 0 °C and the mixture stirred at room temperature overnight.
Water (25 mL) was added to the mixture, which was then extracted with EtOAc (25 mL x
3). The combined organic layers were washed with brine and then dried with Na2SO4.
Crude bis- N, N-acetal was used without purification, 1.94 g, 91% yield. 1H NMR (400
MHz, CDCl3) δ 3.62 (t, 9H), 2.84 (s, 2H), 2.47 – 2.36 (m, 8H). 13C NMR (101 MHz,
CDCl3) δ 81.67, 67.02, 52.02.
Di(piperidin-1-yl)methane. Prepared using the procedure described for
dimorpholinomethane, using the corresponding secondary amine. 1H NMR (400 MHz,
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CDCl3) δ 2.78 (s, 2H), 2.40 – 2.30 (m, 8H), 1.54 – 1.44 (m, 8H), 1.42 – 1.33 (m, 4H). 13C
NMR (101 MHz, CDCl3) δ 82.86, 53.14, 26.03, 25.03.
Bis(4-methylpiperazin-1-yl)methane. Prepared using the procedure described
for dimorpholinomethane, using the corresponding secondary amine.
Bis(2,6-dimethylmorpholino)methane. Prepared using the procedure described
for dimorpholinomethane, using the corresponding secondary amine.
3-(chloromethyl)oxazolidin-2-one. Paraformaldehyde (86 mg, 2.87 mmol) was
added to a mixture of 2-oxazolidinone (250 mg, 2.87 mmol) in TMSCl (1.45 mL, 2.0 M).
The resulting mixture stirred at room temperature for 2 h. Removal of TMSCl in vacuo
afforded the chloro-acetal, which was used crude (quant. yield). 1H NMR (400 MHz,
CDCl3) δ 5.19 (s, 2H), 4.35 – 4.29 (m, 2H), 3.71 – 3.64 (m, 2H). 13C NMR (101 MHz,
CDCl3) δ 156.94, 62.16, 56.20, 42.50.
(R)-3-(chloromethyl)-4-isopropyloxazolidin-2-one. Prepared using the
procedure described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding
oxazolidinone derivative.
(S)-3-(chloromethyl)-4-isopropyloxazolidin-2-one. Prepared using the
procedure described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding
oxazolidinone derivative.
(S)-3-(chloromethyl)-4-phenyloxazolidin-2-one. Prepared using the procedure
described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding oxazolidinone
derivative.
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(R)-4-benzyl-3-(chloromethyl)oxazolidin-2-one. Prepared using the procedure
described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding oxazolidinone
derivative.
2-bromo-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1-one. To 1-((2nitrophenyl)sulfonyl)piperazine (0.150 g, 0.553 mmol) in DCM (2.6 mL, 0.2 M) was
added DIPEA (0.1 mL, 0.553 mmol). The mixture was cooled to 0 °C and bromoacetyl
chloride (0.05 mL, 0.608 mmol) was added dropwise, and then the mixture reacted
overnight at room temperature. After quenching with HCl (5 mL, 0.1 M), more water was
added and the product was extracted with EtOAc (25 mL x 3). The combined organic
layers were washed with brine and then dried with Na2SO4. Silica-gel column
chromatography (product elutes at 65% EtOAc) yielded 181 mg of the desired
compound, 83% yield. 1H NMR (400 MHz, CDCl3) δ 7.97 (dd, 1H), 7.77 – 7.68 (m, 2H),
7.64 (dd, J = 7.3, 1.8, 0.8 Hz, 1H), 4.05 (s, 1H), 3.84 (s, 1H), 3.70 (t, J = 5.2 Hz, 2H),
3.61 (t, J = 5.9, 3.5 Hz, 2H), 3.40 (t, J = 5.8 Hz, 2H), 3.30 (t, 2H). 13C NMR (101 MHz,
CDCl3) δ 165.50, 148.35, 134.31, 131.94, 131.05, 131.00, 124.42, 46.58, 45.93, 45.74,
45.57, 25.49.
2-((4-(2-bromoacetyl)piperazin-1-yl)sulfonyl)benzonitrile. Prepared using the
procedure described for 2-bromo-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1one, using the corresponding piperazine derivative.
4-((2-cyanophenyl)sulfonyl)piperazine-1-sulfonyl chloride. Chlorosulfonic acid
(0.400 mL, 5.88 mmol) was added dropwise to 2-(piperazin-1-ylsulfonyl)benzonitrile
(0.492 g, 1.96 mmol) in chloroform at 0 °C. The reaction was allowed to warm to room
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temperature as it stirred for 30 min. Sat. NaHCO3 was added and the mixture was
extracted with EtOAc (25 mL x 3), and then the combined organic layers were washed
with brine and dried with Na2SO4. This intermediate (0.152 g, 0.459 mmol) was
dissolved in benzene (9.2 mL, 0.05 M) and PCl5 (0.096 g, 0.459 mmol) was added. The
resulting mixture was refluxed for 24 h, filtered and concentrated to dryness, and the
sulfonyl chloride was used crude without purification.
4-((2-cyanophenyl)sulfonyl)piperazine-1-carbonyl chloride. Triphosgene
(0.082 g, 0.277 mmol) was dissolved in DCM (4.1 mL) and pyridine (0.045 mL, 0.553
mmol) was added at 0 °C. 2-(piperazin-1-ylsulfonyl)benzonitrile (0.150 g, 0.553 mmol)
in DCM (4.1 mL) was slowly added and the mixture stirred at room temperature
overnight. After quenching with HCl (5 mL, 1 M) the product was extracted with DCM,
washed with brine and dried with Na2SO4. The product was used crude without
purification.
2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1yl)sulfonyl)benzonitrile. To 2-benzyl-1H-benzo[d]imidazole (43 mg, 0.207 mmol) and
2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile (61 mg, 0.207 mmol) in DCM
(1.4 mL, 0.15 M) was added Hf(OTf)4 (8 mg, 0.0104 mmol). The reaction was allowed to
stir at room temperature for 2 h and then was quenched with sat. NaHCO3. The mixture
was diluted with more DCM, and the organic layer was separated and then dried with
Na2SO4. The product was obtained as a mixture of the desired aminal and starting
materials, and could not be purified.
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2-benzyl-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)methyl)-1Hbenzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1Hbenzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-benzyl-1-((4-tosylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole. Prepared
using the procedure described for 2-((4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the corresponding benzimidazole
and N,O-acetal. 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 6.3, 1.9, 1.0 Hz, 1H), 7.73 –
7.63 (m, 2H), 7.49 – 7.17 (m, 10H), 4.58 (s, 2H), 4.40 (s, 2H), 2.97 (t, 4H), 2.55 (t, 4H),
2.55 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 153.69, 143.97, 142.44, 136.43, 136.01,
132.60, 129.88, 128.79, 128.54, 127.91, 127.03, 122.84, 122.38, 119.77, 109.70, 64.89,
49.73, 45.70, 34.79, 21.71.
2-benzyl-1-((4-((2,4,6-trichlorophenyl)sulfonyl)piperazin-1-yl)methyl)-1Hbenzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1Hbenzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-((4-((2-(2-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1yl)sulfonyl)benzonitrile. Prepared using the procedure described for 2-((4-((2-benzyl1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-(2-methoxybenzyl)-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)methyl)1H-benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1H-
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benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-(2-methoxybenzyl)-1-((4-tosylpiperazin-1-yl)methyl)-1Hbenzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1Hbenzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-(benzylthio)-5-methoxy-1-((4-tosylpiperazin-1-yl)methyl)-1Hbenzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1Hbenzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-((4-((2-(benzylthio)-5-methoxy-1H-benzo[d]imidazol-1-yl)methyl)piperazin1-yl)sulfonyl)benzonitrile. Prepared using the procedure described for 2-((4-((2-benzyl1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-(benzylthio)-5-methoxy-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1yl)methyl)-1H-benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
2-((4-((2-phenyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1yl)sulfonyl)benzonitrile. Prepared using the procedure described for 2-((4-((2-benzyl1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
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2-((4-((2-((2,4-dichlorophenoxy)methyl)-1H-benzo[d]imidazol-1yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile. Prepared using the procedure described
for 2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1yl)sulfonyl)benzonitrile, using the corresponding benzimidazole and N,O-acetal.
2-((2,4-dichlorophenoxy)methyl)-1-((4-tosylpiperazin-1-yl)methyl)-1Hbenzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1Hbenzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the
corresponding benzimidazole and N,O-acetal.
4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine. 2-benzyl-1Hbenzo[d]imidazole (42 mg, 0.205 mmol), dimorpholinomethane (42 mg, 0.226 mmol)
and K2CO3 (31 mg, 0.226 mmol) were suspended in DCM (1.25 mL, 0.167 M). Succinic
anhydride (23 mg, 0.226 mmol) was added and the reaction stirred at room temperature
for 1 h. The reaction was diluted with more DCM (25-50 mL) and washed with 1 M
NaOH (25 mL x 2), followed by brine (10 mL). The organic layer was dried over Na2SO4
and concentrated to dryness, affording the desired product, which was not purified. 1H
NMR (400 MHz, CDCl3) δ 7.79 – 7.72 (m, 1H), 7.42 – 7.34 (m, 1H), 7.32 – 7.16 (m,
7H), 4.46 (s, 2H), 4.40 (s, 2H), 3.59 (t, 4H), 2.37 (t, 4H). 13C NMR (101 MHz, CDCl3) δ
153.78, 142.31, 136.36, 136.05, 128.73, 128.53, 126.93, 122.57, 122.10, 119.50, 109.74,
66.47, 65.44, 50.81, 34.71.
2-benzyl-1-(piperidin-1-ylmethyl)-1H-benzo[d]imidazole. Prepared using the
procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine,
using the corresponding bis- N, N-acetal. 1H NMR (400 MHz, CDCl3) δ 7.81 – 7.72 (m,
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1H), 7.43 – 7.34 (m, 1H), 7.31 – 7.15 (m, 7H), 4.43 (s, 4H), 2.36 (t, J = 5.2 Hz, 4H), 1.56
– 1.45 (m, 4H), 1.46 – 1.37 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 154.08, 142.37,
136.59, 136.32, 128.68, 128.66, 126.82, 122.35, 121.86, 119.39, 109.90, 66.01, 51.85,
34.75, 25.58, 24.21.
2-benzyl-1-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole. Prepared
using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding bis- N, N-acetal. 1H NMR (400 MHz,
CDCl3) δ 7.81 – 7.71 (m, 1H), 7.43 – 7.34 (m, 1H), 7.35 – 7.17 (m, 7H), 4.47 (s, 2H),
4.41 (s, 2H), 2.49 – 2.31 (m, 8H), 2.26 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 153.68,
142.02, 136.19, 135.84, 128.52, 128.41, 126.70, 122.34, 121.85, 119.15, 109.69, 65.00,
54.33, 50.15, 45.71, 34.43.
4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-2,6-dimethylmorpholine.
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding bis- N, N-acetal. 1H NMR (400 MHz,
CDCl3) δ 7.70 – 7.63 (m, 1H), 7.34 – 7.26 (m, 1H), 7.22 – 7.02 (m, 7H), 4.36 (s, 2H),
4.29 (s, 2H), 3.50 – 3.36 (m, 2H), 2.46 – 2.35 (m, 2H), 1.65 (t, 2H), 0.98 (d, 6H). 13C
NMR (101 MHz, CDCl3) δ 153.73, 142.25, 136.35, 135.97, 128.73, 128.57, 126.96,
122.61, 122.15, 119.37, 110.05, 71.37, 65.25, 56.44, 34.63, 18.97.
4-((2-(cyclohexylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine.
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.1H
NMR (400 MHz, CDCl3) δ 7.73 – 7.68 (m, 1H), 7.42 – 7.37 (m, 1H), 7.24 – 7.19 (m,
2H), 4.66 (s, 2H), 3.65 (t, 4H), 2.80 (d, J = 7.1 Hz, 2H), 2.51 (t, J = 5.7, 3.7 Hz, 4H), 2.05
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– 1.94 (m, 1H), 1.83 – 1.60 (m, 4H), 1.30 – 0.99 (m, 6H). 13C NMR (101 MHz, CDCl3) δ
155.25, 142.60, 135.74, 122.19, 122.05, 119.26, 109.85, 66.69, 65.49, 51.08, 37.54,
35.39, 33.56, 26.39, 26.24.
4-((2-(2-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine.
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.
4-((2-(pyridin-3-ylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine.
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.
4-((2-(4-bromobenzyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine.
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.
4-((2-benzyl-4-nitro-1H-benzo[d]imidazol-1-yl)methyl)morpholine. Prepared
using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.
4-((2-benzyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl)morpholine. Prepared
using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.
4-((8-benzyl-9H-purin-9-yl)methyl)morpholine. Prepared using the procedure
described for 4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine, using the
corresponding benzimidazole and bis- N, N-acetal.
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4-((2-benzyl-5,6-dichloro-1H-benzo[d]imidazol-1-yl)methyl)morpholine.
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.
3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one. 2-benzyl-1Hbenzo[d]imidazole (58 mg, 0.279 mmol) was dissolved in DMF (1.4 mL, 0.2 M) and
NaH was added in two portions (7 mg, 0.294 mmol). The mixture was allowed to stir at
room temperature for 30-45 min. 3-(chloromethyl)oxazolidin-2-one (40 mg, 0.294 mmol)
was added dropwise (in DMF) and the reaction stirred at room temperature for 2 h. Water
(50 mL) was added and the product was extracted with EtOAc (25 mL x3), and then the
combined organic layers were washed with brine (50 mL x 3). After drying on Na2SO4
the product was purified using alumina column chromatography. 1H NMR (400 MHz,
CDCl3) δ 7.83 – 7.76 (m, 1H), 7.49 – 7.43 (m, 1H), 7.37 – 7.21 (m, 7H), 5.53 (s, 2H),
4.41 (s, 2H), 4.07 (t, 2H), 3.01 (t, 2H). 13C NMR (101 MHz, CDCl3) δ 157.65, 153.15,
142.66, 136.21, 134.95, 129.07, 128.70, 127.40, 123.49, 122.98, 119.94, 109.67, 61.95,
52.57, 42.73, 34.28.
3-((2-(pyridin-3-ylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2one. Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)oxazolidin-2-one, using the corresponding benzimidazole.
3-((2-benzyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl)oxazolidin-2-one. Prepared
using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)oxazolidin-2-one, using the corresponding benzimidazole.
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3-((8-benzyl-7H-purin-7-yl)methyl)oxazolidin-2-one. Prepared using the
procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2one, using the corresponding benzimidazole.
(R)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2one. Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 1H NMR
(400 MHz, CDCl3) δ 7.79 – 7.73 (m, 1H), 7.43 – 7.37 (m, 1H), 7.30 – 7.17 (m, 7H), 5.81,
5.20 (ABq, JAB= 14.9 Hz, 2H), 4.46, 4.31 (ABq, JAB= 15.9 Hz, 2H), 3.96 (dd, J = 9.1, 3.8
Hz, 1H), 3.77 (t, J = 9.0 Hz, 1H), 3.35 – 3.28 (m, 1H), 1.98 - 1.86 (m, 1H), 0.73 (dd, J =
19.8, 6.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 157.73, 153.05, 142.66, 136.05,
135.05, 128.97, 128.33, 127.19, 123.38, 122.82, 119.93, 109.38, 62.69, 57.69, 50.50,
33.91, 27.56, 17.77, 13.72.
(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2one. Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 1H NMR
(400 MHz, CDCl3) δ 7.79 – 7.72 (m, 1H), 7.42 – 7.36 (m, 1H), 7.32 - 7.15 (m, 7H), 5.81,
5.20 (ABq, JAB= 14.9 Hz, 2H), 4.46, 4.29 (ABq, J = 15.8 Hz, 2H), 3.97 (dd, J = 9.1, 3.7
Hz, 1H), 3.77 (t, J = 9.0 Hz, 1H), 3.35 - 3.27 (m, 1H), 1.96 – 1.87 (m, 1H), 0.73 (dd, J =
20.8, 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 157.78, 153.11, 142.72, 136.10,
135.11, 129.03, 128.38, 127.25, 123.45, 122.90, 120.01, 109.41, 62.74, 57.73, 50.54,
33.99, 27.63, 17.83, 13.78.
(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-phenyloxazolidin-2-one.
Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1-
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yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 1H NMR
(400 MHz, CDCl3) δ 7.77 – 7.72 (m, 1H), 7.52 – 7.46 (m, 2H), 7.33 – 7.27 (m, 2H), 7.247.15 (m, 7H), 6.97 – 6.91 (m, 2H), 5.79, 4.97 (ABq, JAB= 14.8 Hz, 2H), 4.43 – 4.31 (m,
2H), 4.24, 3.61 (ABq, JAB= 15.9 Hz, 2H), 4.01 (dd, J = 7.4, 5.1 Hz, 1H).

13

C NMR (101

MHz, CDCl3) δ 157.82, 153.43, 142.73, 136.97, 136.12, 130.08, 130.05, 129.27, 129.24,
129.03, 128.35, 127.25, 127.06, 123.44, 123.05, 119.88, 110.16, 70.42, 58.07, 50.63,
33.91.
(R)-4-benzyl-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one.
Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 1H NMR
(400 MHz, CDCl3) δ 7.86 – 7.78 (m, 1H), 7.46 – 7.39 (m, 1H), 7.36 – 7.19 (m, 10H),
6.98 – 6.91 (m, 2H), 5.83, 5.41 (ABq, JAB= 15.0 Hz, 2H), 4.49, 4.31 (ABq, JAB = 15.8
Hz, 2H), 3.89 (dd, J = 8.9, 3.6 Hz, 1H), 3.70 (t, J = 8.5 Hz, 1H), 3.65 – 3.56 (m, 1H),
2.97 (dd, J = 13.6, 4.2 Hz, 1H), 2.50 (dd, J = 13.6, 9.4 Hz, 1H). 13C NMR (101 MHz,
CDCl3) δ 157.60, 153.50, 142.93, 136.27, 135.32, 134.82, 129.37, 129.34, 129.19,
128.66, 127.79, 127.43, 127.19, 123.63, 123.20, 120.32, 109.50, 67.01, 54.94, 51.13,
38.35, 34.06.
2-((4-(2-benzyl-1H-benzo[d]imidazole-1-carbonyl)piperazin-1yl)sulfonyl)benzonitrile. To 2-benzyl-1H-benzo[d]imidazole (173 mg, 0.832 mmol) in
DCM (2.8 mL, 0.3 M) was added 4-((2-cyanophenyl)sulfonyl)piperazine-1-carbonyl
chloride (261 mg, 0.832 mmol) and DIPEA (0.3 mL, 1.664 mmol). The mixture was
heated in a sealed flask overnight at 40 °C and then cooled to room temperature, diluted
with more DCM and washed with sat. NaHCO3. The organic layer was dried on Na2SO4,
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concentrated and purified via silica-gel column chromatography. 1H NMR (400 MHz,
CDCl3) δ 8.00 (dd, 1H), 7.88 (dd, 1H), 7.80 – 7.68 (m, 3H), 7.32 – 7.08 (m, 8H), 3.72 (s,
2H), 3.72 (t, J = 5.0 Hz, 2H), 3.55 (t, J = 5.1 Hz, 2H), 3.15 (t, J = 5.1 Hz, 2H), 3.06 (t, J =
5.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 169.71, 139.85, 135.79, 134.48, 133.17,
130.56, 129.03, 128.81, 128.59, 127.59, 127.21, 126.91, 116.15, 111.03, 109.56, 49.88,
45.79, 45.74, 45.61, 41.17.
2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)sulfonyl)piperazin-1yl)sulfonyl)benzonitrile. To 2-benzyl-1H-benzo[d]imidazole (152 mg, 0.730 mmol) in
DMF (3.0 mL, 0.25 M) was added NaH (21 mg, 0.876 mmol). The reaction stirred at
room temperature for 30 min and then 4-((2-cyanophenyl)sulfonyl)piperazine-1-sulfonyl
chloride (255 mg, 0.730 mmol) was added dropwise (in DMF), after which the reaction
was allowed to stir overnight. Water (50 mL) was added and the product was extracted
with EtOAc (25 mL x3), and then the combined organic layers were washed with brine
(50 mL x 3). After drying on Na2SO4 the product was purified using silica-gel column
chromatography.
2-((4-(2-(2-benzyl-1H-benzo[d]imidazol-1-yl)acetyl)piperazin-1yl)sulfonyl)benzonitrile. To 2-((4-(2-bromoacetyl)piperazin-1-yl)sulfonyl)benzonitrile
(83 mg, 0.223 mmol) in acetone (2.5 mL, 0.09 M) was added 2-benzyl-1Hbenzo[d]imidazole (47 mg, 0.223 mmol) and KOH (25 mg, 0.446 mmol). The reaction
stirred at 60 °C for 2 h. Solvent was removed in vacuo, and the residue was diluted in
water and extracted with chloroform (25 mL x 3). The combined organic layers were
dried on Na2SO4 and concentrated to dryness. Silica-gel column chromatography yielded
the desired product, 42% yield. 1H NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 7.7, 1.4 Hz,
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1H), 7.92 (dd, 1H), 7.83 – 7.69 (m, 3H), 7.25 – 7.05 (m, 8H), 4.60 (s, 2H), 4.26 (s, 2H),
3.54 (t, 2H), 3.31 (t, 2H), 3.20 (t, 2H), 3.08 (t, 2H). 13C NMR (101 MHz, CDCl3) δ
164.20, 153.10, 142.50, 139.91, 135.93, 135.85, 133.40, 133.32, 130.66, 128.99, 128.70,
127.22, 122.83, 122.34, 119.83, 116.21, 110.90, 108.98, 45.58, 45.39, 44.89, 44.39,
41.55, 34.95.
2-(2-benzyl-1H-benzo[d]imidazol-1-yl)-1-(4-((2nitrophenyl)sulfonyl)piperazin-1-yl)ethanone. Prepared using the procedure described
for 2-((4-(2-(2-benzyl-1H-benzo[d]imidazol-1-yl)acetyl)piperazin-1yl)sulfonyl)benzonitrile, using the corresponding alkyl bromide derivative. 1H NMR (400
MHz, CDCl3) δ 7.91 (dd, 1H), 7.74 – 7.65 (m, 3H), 7.61 (dd, J = 7.1, 2.1 Hz, 1H), 7.21 –
7.03 (m, 8H), 4.55 (s, 2H), 4.21 (s, 2H), 3.47 (t, J = 4.8 Hz, 2H), 3.20 (t, J = 4.8 Hz, 2H),
3.15 – 3.08 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 164.11, 153.19, 148.25, 142.39,
135.85, 134.38, 131.93, 131.03, 128.84, 128.67, 128.64, 127.07, 124.28, 122.67, 122.17,
119.58, 109.09, 45.52, 45.42, 44.65, 44.36, 41.56, 34.73.
1,4-bis(methoxymethyl)piperazine. Paraformaldehyde (697 mg, 23.22 mmol
mmol) was added to a mixture piperazine (500 mg, 5.81 mmol), K2CO3 (3.21 g, 23.22
mmol) and Na2SO4 (3.30 g, 23.22 mmol) in methanol (20 mL, 0.3 M). The mixture
stirred at room temperature overnight, and then was filtered and washed with ether.
Removal of solvent in vacuo yielded 613 mg of the bis- N, O-acetal, 71% yield. This
intermediate was used crude in the next step.
1,4-bis((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazine. To 2-benzyl1H-benzo[d]imidazole (196 mg, 0.941 mmol) and 1,4-bis(methoxymethyl)piperazine (82
mg, 0.471 mmol) in DCM (3.2 mL, 0.15 M) was added Hf(OTf)4 (36 mg, 0.0471 mmol).
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The reaction was allowed to stir at room temperature for 2 h and then was quenched with
sat. NaHCO3. The mixture was diluted with more DCM, and the organic layer was
separated and then dried with Na2SO4. The product was obtained as a mixture of the
desired aminal and starting materials, and could not be purified.
4-((5-benzyl-1H-tetrazol-1-yl)methyl)morpholine. To 5-benzyl-1H-tetrazole
(94 mg, 0.587 mmol) in methanol (3 mL, 0.2 M) at 0 °C was added morpholine (0.056
mL, 0.645 mmol). The mixture stirred at 0 °C for 15 min and then formalin (0.053 mL,
0.704 mmol) was added. Reaction was kept at 0 °C for 1 h and then was allowed to warm
to room temperature overnight. The product was obtained after removal of solvent in
vacuo, and was not purified.
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(R)-4-benzyl-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one

39

(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-phenyloxazolidin-2-one
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(R)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2-one
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(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2-one
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3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one
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4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine
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2-benzyl-1-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole
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2-benzyl-1-(piperidin-1-ylmethyl)-1H-benzo[d]imidazole
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4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-2,6-dimethylmorpholine
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4-((2-(cyclohexylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine
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2-((4-(2-benzyl-1H-benzo[d]imidazole-1-carbonyl)piperazin-1-yl)sulfonyl)benzonitrile
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2-((4-(2-(2-benzyl-1H-benzo[d]imidazol-1-yl)acetyl)piperazin-1-yl)sulfonyl)benzonitrile
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2-(2-benzyl-1H-benzo[d]imidazol-1-yl)-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethanone
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2-benzyl-1-((4-tosylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole
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2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile

2-benzyl-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazole
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2-benzyl-5,6-dichloro-1H-benzo[d]imidazole
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2-((2,4-dichlorophenoxy)methyl)-1H-benzo[d]imidazole
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Dimorpholinomethane
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Di(piperidin-1-yl)methane
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3-(chloromethyl)oxazolidin-2-one
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2-bromo-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1-one
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Chapter 2
Development of photolabile protecting groups for a bioactive compound
Introduction
Quorum sensing (QS) is a communication mechanism that occurs in many
bacteria. An underlying principle of QS is that bacteria utilize their population density to
modify the collective behavior of the group. Organisms that are involved in QS produce
small molecule signals known as autoinducers, which are released into their environment
after they are synthesized intracellularly. The bacteria, using specific receptors, can then
recognize these autoinducers in order to probe the population density. Binding of these
signal molecules typically brings forth changes to gene expression, which is the driving
factor that allows a given population of cells to modify their behavior in unison.
Importantly, many known virulence factors are produced as a result of QS, and so this
signaling mechanism controls how/when a bacterium becomes pathogenic or virulent.
Coupled to the issue of growing antibiotic resistance, QS has recently gained exposure as
a potential alternative to these medicines. While no QS drugs are currently on the market,
much research has been published on the topic, and several studies have provided support
for the idea of using these molecules as a novel means of dealing with bacterial
infections.
Photoremovable protecting groups, or "photocages", are a relatively new tool that
has successfully been employed to study various biological and biochemical
systems1,15,16. After a photocage has been applied to a biologically active molecule, that
compound is said to be "caged", and decaging (photorelease) is achieved via irradiation
of light at a certain wavelength. Light-activation is an optimal control element, as it can
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be managed in regard to location, timing, and magnitude1,2,3. Additionally, photodecaging
provides a concentration surge, in which the amount of active compound jumps from zero
to a maximum level in seconds (or even milli/micro seconds). While the concept as a
whole is without doubt scientifically practical, the degree of effectiveness usually
depends on the specific photocage that is chosen for the given assay. Many examples of
photocages are known and most differ in the various photorelease characteristics, such as
optimal release wavelength, quantum yield, time required for photorelease and solubility.
Ortho-nitrobenzyl (ONB) photocages are a class that has been widely explored due to the
fact that they possess several ideal properties, including synthetic straightforwardness1. A
subset of this ONB class was employed in this investigation to study QS.
The specific goals of this experiment were to utilize a riboswitch, which is
activated by a photocaged organic molecule (theophylline), to study QS in biofilms. The
riboswitch controls production of a protein known as HapR, an important QS regulator in
V. cholera5,6. We were interested in caging theophylline with a certain ONB known as
NPOM, which was developed as a cage for NH heterocycles that improved upon similar
cages in regards to stability, decaging time, and the production of less toxic byproducts.
A previous study has employed NPOM-caged theophylline to activate a ribozyme, and
thus has provided a basis for a similar system to be used to photochemically control gene
expression1.
Results and Discussion
Development of the HapR-riboswitch construct. Initial attempts to set up the
riboswitch with the other necessary components proved to be somewhat problematic. The
riboswitch was first linked to a fluorescent protein, mKate, in E. coli. While this was
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successful, the ultimate goal was to have a construct consisting of the riboswitch with
mKate and HapR in V. cholera. Conjugating the plasmid containing the HapR riboswitch
from E. coli to V. cholera was an issue, and as a result, initial assays were performed in
the E. coli strain. Eventually, a V. cholera strain was produced that contained the desired
construct (the riboswitch connected to HapR and mKate), and phenotypic data was
produced for confirmation. The characteristic rugose morphology of the HapR strain is
complemented when grown on plates containing theophylline, changing to a smooth
morphology as a result of the expression of HapR. Having constructed the necessary
bacterial strain, we focused our attention on developing a means of photochemical
control for the riboswitch.
Analysis of NPOM-caged theophylline. Early trials involving the NPOM-caged
theophylline produced promising results; the compound decaged as hoped and
photorelease could indeed be monitored via fluorescence measurements. The compound,
unfortunately, was only able to produce a modest increase in gene expression (4-5 fold)
when tested in vitro. In comparison, free theophylline induced a 150-fold increase in gene
expression. The level of response from the caged molecules most likely does not need to
be this intense, and so we aimed for around a 20-fold increase. As we further assessed the
NPOM-caged theophylline it was observed to be poorly soluble in polar solvents,
specifically methanol (used to make stock solutions) and water (used in the LB media).
The compound was only partially soluble at the working concentration (2 mM), and thus
it was hypothesized that this lack of solubility was causing the caged theophylline to
under-perform in the assay. Photorelease was tested in solution without cells and
determined to occur to an appreciable extent, which supported the idea that aqueous

62

solubility was limiting the caged compound's ability to cause a significant biological
response.
Discovery and evaluation of new photocages. To test this theory, several new
photocages were prepared and linked to theophylline. Since the NPOM cage experienced
poor solubility in polar solvents, these new cages were designed to contain some type of
polar functionality. Since the ortho-nitro group is essential for photorelease, we decided
to focus on the substituents on the other side of the ring. Initially, it was thought that
changing the methylenedioxy group to a diol (a cathecol derivative) would significantly
increase polarity. This analog was ultimately abandoned due to synthetic difficulties, as it
was determined that the cage could not contain any exposed nucleophiles in order to
complete the last steps of the route. Following this revelation, three new photocages were
successfully prepared, each derived from the NPOM starting material. Surprisingly, these
derivatives all underwent decaging at 365 nm, and produced a range of both solubility
and riboswitch activation. 2, theophylline caged by an ONB analog containing an orthomethoxy-thiomethyl moiety, was found to have the lowest solubility of the four
compounds prepared, and accordingly, caused the smallest increase of gene expression.
In contrast, 4, another ONB analog that contained an ortho-di-diethyleneglycolmonomethyl ether group, was observed to be fully soluble in polar solvents at a range of
concentrations, including the working concentration of the assay. Unfortunately, the
fluorescence response level of this compound was not substantially different from that of
the original NPOM-theophylline. Finally, an additional ONB cage was synthesized and
linked to theophylline, containing an ortho-methoxy nitrile moiety (2). Similar to 4, this
new nitrile compound also possessed improved aqueous solubility, being fully soluble at
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2 mM. On the other hand, this molecule was found to have unique photorelease
properties, producing a biological response that was nearly quadruple that of NPOMtheophylline, after one minute of irradiation. Since the highly polar diethyleneglycol
derivative did not perform well in vitro, it can be assumed that solubility does not entirely
explain the high response level in 2. Instead, the electronic effect of the nitrile on the
decaging process is likely to play an important role as well.
Chemistry
Synthesis of NPOM-theophylline was based of a previously published route to
NPOM-Cl, with minor adjustments. Rather than starting with the nitrated secondary
alcohol substrate, which was fairly expensive (>$100/g), we choose start a few steps
prior, with 3′,4′-(Methylenedioxy)acetophenone, which is significantly cheaper. Nitration
at the desired position ortho to the ketone was achieved in 74% yield. Although
selectivity was a concern, no other regioisomers were isolated after purification.
Reduction of the ketone to the secondary alcohol via sodium borohydride proceeded
either very well or poorly, depending on the batch of NaBH4 that was used. Ultimately it
was concluded that the reaction would give all product if one had access to fresh sodium
borohydride. Converting the alcohol to the chloro-acetal proved to be somewhat
troublesome. Initial attempts focused on obtaining the desired intermediate in one step
from the alcohol, using paraformaldehyde and TMSCl. After a couple failed trials, this
transformation was performed via a two step procedure, first converting the alcohol to a
O, S-acetal (using a MTM ether protecting group), and then reacting this O, S-acetal with
sulfuryl chloride to obtain the chloro-acetal. Finally, theophylline was reacted with NaH
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in order to facilitate the SN2 reaction with NPOM-Cl, which typically proceeded very
smoothly.
Analogs of NPOM were prepared using NPOM (or one of its precursors) as a
starting material, keeping the ONB core consistent. Initial efforts focused on cleaving the
methylenedioxy group to the diol, forming a catechol derivative. After several failed
attempts using BBr3, we switched focuses to making the ortho-methoxy phenol. While
this compound was indeed obtained, it was discovered that the sulfuryl chloride step of
the route did not tolerate any exposed nucleophiles, as sulfonyl esters/amides formed
preferentially to the S, O-acetal reacting to give the desired chloro-acetal. Accordingly,
other NPOM analogs were designed and prepared that did not possess any exposed
nuclephiles, yet still maintained the desired photorelease characteristics. Performing
nucleophilic aromatic substitution on NPOM, three new analogs were synthesized using
either, sodium cyanide, sodium methoxide or the alkoxide salt of diethyleneglycol
monomethylether. Interestingly, it found that SNAr occurred selectively at the position
para to the nitro group. The resulting free phenol that was produced in each case was
functionalized with either a methyl group or another diethyleneglycol monomethylether
chain.
Conclusion
Based off of precedent for the activation of a ribozyme using NPOM-caged
theophylline, a similar study was performed. The previous paper was expanded upon by
using the concept to photochemically control gene expression in a V. cholera strain
consisting of a riboswitch connected to a QS master regulator, HapR, and a fluorescent
protein, mKate. In addition to developing novel biological methods, several new
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photocages were prepared based off of the common NPOM cage, some of which
improved upon solubility as well as in vitro photorelease. These new cages are likely to
be useful in other studies that utilize NPOM-caged compounds, or ONB cages in general,
although they are not completely synthetically straightforward to make. Current goals
include a more detailed investigation into QS in biofilms (specifically in V. cholera
HapR) using the photochemical approach described here. Meanwhile, additional nitrilecontaining ONB caging groups are being developed and will be assessed, as the presence
of that functional group appears to have a positive effect on the decaging process.
Experimental Section
General chemistry
1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethanone. 3,4-methylenedioxyacetophenone
(750 mg, 4.57 mmol) was dissolved in TFA (6.75 ml, 0.67 M) and the solution was
cooled to 0 °C. Sodium nitrite (946 mg, 13.71 mmol) was added portion wise (in 3
portions, CAUTION: very exothermic, reaction foams up significantly after third addition
of NaNO2). The mixture stirred at room temperature for 4 h and then was quenched with
water (50 mL). Product was extracted with EtOAc (25 mL x 3) and the combined organic
layers were washed with sat. NaHCO3 and brine, and then dried with Na2SO4.
Purification via silica-gel flash chromatography (product elutes around 30% EtOAc)
afforded 649 mg of the desired product, 68% yield.
1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethanol. To 1-(6-nitrobenzo[d][1,3]dioxol-5yl)ethanone (350 mg, 1.67 mmol) in a mixture of ethanol and THF (1:1, 18 mL total, 0.1
M) was added NaBH4 (69.5 mg, 1.84 mmol). The reaction stirred overnight at room
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temperature and then HCl was added (5 mL, 1 M). After removal of solvent in vacuo, the
residue was dissolved in EtOAc, washed with brine and dried over Na2SO4. Purification
via silica-gel flash chromatography (product elutes around 30% EtOAc) afforded 342 mg
of the desired alcohol, 97% yield.
5-(1-((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole. To 1-(6nitrobenzo[d][1,3]dioxol-5-yl)ethanol (224 mg, 1.06 mmol) dissolved in acetic acid (2.5
mL, 42.43 mmol) was added DMSO (1.51 mL, 21.22 mmol), followed by acetic
anhydride (2.0 mL, 21.22 mmol) dropwise. The reaction stirred at room temperature for
72 h. Sat. NaHCO3 (50 mL) was added dropwise and the mixture was then extracted with
EtOAc (25 mL x 3). The combined organic layers were washed with brine and dried over
Na2SO4. Purification via silica-gel flash chromatography (product elutes around 25%
EtOAc) afforded 240 mg of the desired alcohol, 83% yield.
5-(1-(chloromethoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole. 5-(1((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (240 mg, 0.885 mmol) was
dissolved in DCM (6 mL, 0.15 M) and the solution was cooled to 0 °C. Sulfuryl chloride
(0.07 mL, 0.885 mmol) was added dropwise and the reaction stirred at 0 °C for 1 h.
Solvent was removed in vacuo, and the product was used crude in the subsequent
reaction, without a workup or purification.
2-hydroxy-5-(1-hydroxyethyl)-4-nitrobenzonitrile. To 1-(6nitrobenzo[d][1,3]dioxol-5-yl)ethanol (116 mg, 0.549 mmol) in HMPA (1.1 mL, 0.5 M)
was added NaCN (27 mg, 0.549 mmol). The reaction stirred at 150 °C for 3 min and then
three additional portions of NaCN was added (0.275 mmol x 3) every 5 minutes. After
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stirring an additional 10 minutes at 150 °C, the reaction was quenched with water and
NaOH. The product was extracted with EtOAc (25 mL x 3) and the combined organic
layers were washed with brine and dried on Na2SO4. Purification via silica-gel flash
chromatography (product elutes around 95% EtOAc) afforded 30 mg of the desired diol,
26% yield.
5-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-hydroxy-4-nitrobenzonitrile. 2hydroxy-5-(1-hydroxyethyl)-4-nitrobenzonitrile (272 mg, 1.31 mmol) was dissolved in
DCM (13 mL, 0.1 M) and cooled to 0 °C. Triethylamine (0.27 mL, 1.97 mmol) was
added followed by TBSCl (196 mg, 1.31 mmol) and DMAP (cat.). The mixture was
allowed to warm to room temperature as it stirred overnight. Additional DCM (50 mL)
was added and the mixture was washed with HCl (25 mL, 1.0 M) and brine, and then was
dried over Na2SO4. Purification via silica-gel flash chromatography (product elutes
around 15% EtOAc) afforded 300 mg of the desired phenol, 71% yield.
5-(1-hydroxyethyl)-2-methoxy-4-nitrobenzonitrile. Prepared using the
procedure described for 2-methoxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile,
using the corresponding phenol derivative.
2-hydroxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile. To 5-(1((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (283 mg, 1.05 mmol) in HMPA
(2.1 mL, 0.5 M) was added NaCN (51.5 mg, 1.05 mmol). The reaction stirred at 150 °C
for 3 min and then three additional portions of NaCN was added (0.502 mmol x 3) every
5 minutes. After stirring an additional 10 minutes at 150 °C, the reaction was quenched
with water and NaOH. The product was extracted with EtOAc (25 mL x 3) and the
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combined organic layers were washed with brine and dried on Na2SO4. Purification via
silica-gel flash chromatography (product elutes around 55% EtOAc) afforded 51 mg of
the desired phenol, 17% yield.
2-methoxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile. To 2hydroxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile (51 mg, 0.181 mmol) in
DMF (2 mL, 0.1 M) was added K2CO3 (50 mg, 0.362 mmol) and methyl iodide (0.02
mL, 0.362 mmol). The mixture stirred at room temperature overnight, and then the
reaction was quenched with water. The product was extracted with EtOAc (25 ml x 3),
and the combined organic layers were washed with brine (50 mL x 3).
5-(1-(chloromethoxy)ethyl)-2-methoxy-4-nitrobenzonitrile. Prepared using the
procedure described for 5-(1-(chloromethoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole, using
the corresponding MTM ether derivative.
2-(methylthio)-4-(1-((methylthio)methoxy)ethyl)-5-nitrophenol. To 5-(1((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (283 mg, 1.05 mmol) in HMPA
(2.1 mL, 0.5 M) was added NaCN (51.5 mg, 1.05 mmol). The reaction stirred at 150 °C
for 3 min and then three additional portions of NaCN was added (0.502 mmol x 3) every
5 minutes. After stirring an additional 10 minutes at 150 °C, the reaction was quenched
with water and NaOH. The product was extracted with EtOAc (25 mL x 3) and the
combined organic layers were washed with brine and dried on Na2SO4. Purification via
silica-gel flash chromatography (product elutes around 45% EtOAc) afforded 65 mg of
the desired phenol, 20% yield.
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(2-methoxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrophenyl)(methyl)sulfane.
Prepared using the procedure described for 2-methoxy-5-(1-((methylthio)methoxy)ethyl)4-nitrobenzonitrile, using the corresponding phenol derivative.
(5-(1-(chloromethoxy)ethyl)-2-methoxy-4-nitrophenyl)(methyl)sulfane.
Prepared using the procedure described for 5-(1-(chloromethoxy)ethyl)-6nitrobenzo[d][1,3]dioxole, using the corresponding MTM ether derivative.
4-(1-hydroxyethyl)-2-(2-(2-methoxyethoxy)ethoxy)-5-nitrophenol. To
diethylene glycol monomethylether (0.28 mL, 2.38 mmol) in DMSO (1.5 mL, 0.5 M)
was added NaH (114 mg, 2.86 mmol) in two portions. The mixture was stirred at 150 °C
for 20 min and then 5-(1-((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (323
mg, 1.191 mmol) was added dropwise (in 1 mL DMSO). After stirring at 150 °C for an
additional 15 min, the mixture was cooled to room temperature and quenched with water
and 1 M HCl. The product was extracted with EtOAc (30 mL x 3) and then the combined
organic layers were washed with NaHCO3 and brine (x 2), and then dried over Na2SO4,
affording 326 mg of the desired phenol, 90% yield.
4-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(2-(2-methoxyethoxy)ethoxy)-5nitrophenol. Prepared using the procedure described for 5-(1-((tertbutyldimethylsilyl)oxy)ethyl)-2-hydroxy-4-nitrobenzonitrile, using the diol derivative.
Purification via silica-gel flash chromatography (product elutes around 15% EtOAc)
afforded 179.4 mg of the desired phenol, 40% yield.
2-(2-methoxyethoxy)ethyl 4-methylbenzenesulfonate. Solid NaOH (0.583 g,
14.56 mmol) was dissolved in water (2.91 mL) and the solution was chilled to 0 °C.
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Diethyleneglycol monomethylether (500 mg, 0.489 mL, 4.16 mmol) was added dropwise
(in 1.25 mL THF), followed by tosyl chloride (0.952 g, 4.994 mmol) also dropwise, in
2.9 mL THF. The mixture stirred overnight at room temperature and then the solvent was
removed in vacuo. EtOAc (50 mL) was added and the mixture was washed with 1 M
NaOH and then brine. After drying over Na2SO4 the product was used crude in the
subsequent step.
1-(4,5-bis(2-(2-methoxyethoxy)ethoxy)-2-nitrophenyl)ethanol. A solution of 2(2-methoxyethoxy)ethyl 4-methylbenzenesulfonate (85 mg, 0.3084 mmol) in 2 mL ACN
was added to a mixture of 4-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(2-(2methoxyethoxy)ethoxy)-5-nitrophenol (106.6 mg, 0.257 mmol) and K2CO3 (43 mg, 0.384
mmol) in 3.2 mL ACN. The reaction was refluxed at 70 °C overnight and then was
concentrated to dryness. EtOAc (50 mL) was added and then the mixture was washed
with sat. NaHCO3 and then brine. Drying over Na2SO4 and concentration in vacuo
afforded 122.2 mg of the desired product, which was used crude without purification.
((1-(4,5-bis(2-(2-methoxyethoxy)ethoxy)-2nitrophenyl)ethoxy)methyl)(methyl)sulfane. Prepared using the procedure described
for 5-(1-((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole, using the
corresponding alcohol derivative.
1-(1-(chloromethoxy)ethyl)-4,5-bis(2-(2-methoxyethoxy)ethoxy)-2nitrobenzene. Prepared using the procedure described for 5-(1-(chloromethoxy)ethyl)-6nitrobenzo[d][1,3]dioxole, using the corresponding MTM ether derivative.
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1,3-dimethyl-7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1Hpurine-2,6(3H,7H)-dione. NaH (25.5 mg, 1.062 mmol) was added (in two portions) to
theophylline (160 mg, 0.885 mmol) in DMF (3 mL) and the mixture stirred at room
temperature for 45 min. 5-(1-(chloromethoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (229
mg, 0.885 mmol) was dissolved in DMF (1.5 mL) and added dropwise to the stirring
mixture, and then the reaction continued stirring for 1.5 h at room temperature. EtOAc
(50 mL) was added and the mixture was washed with sat. NaHCO3 and brine (30 mL x
3). After drying over Na2SO4 the product was purified via alumina flash chromatography,
eluting after 75% EtOAc. 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.41 (s, 1H), 7.02
(s, 1H), 6.07 (s, 2H), 5.63 (s, 2H), 5.35 (q, J = 6.3 Hz, 1H), 3.54 (s, 3H), 3.37 (s, 3H),
1.48 (d, J = 6.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 155.12, 152.27, 151.58, 148.69,
147.19, 141.97, 141.75, 136.52, 106.18, 106.14, 105.00, 103.16, 74.25, 73.32, 29.94,
28.16, 23.75.
7-((1-(4-methoxy-5-(methylthio)-2-nitrophenyl)ethoxy)methyl)-1,3-dimethyl1H-purine-2,6(3H,7H)-dione. Prepared using the procedure described for 1,3-dimethyl7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1H-purine-2,6(3H,7H)-dione,
using the corresponding chloro-acetal derivative. 1H NMR (400 MHz, CDCl3) δ 7.64 (s,
1H), 7.30 (s, 1H), 7.02 (s, 1H), 5.74, 5.63 (ABq, JAB = 11.2 Hz, 2H), 5.44 (q, 1H), 3.89 (s,
3H), 3.49 (s, 3H), 3.33 (s, 3H), 2.40 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H). 13C NMR (101
MHz, CDCl3) δ 155.07, 154.18, 151.39, 148.52, 143.95, 141.53, 137.20, 132.79, 121.11,
121.08, 104.32, 75.18, 74.81, 56.50, 29.84, 28.03, 24.05, 13.88.
5-(1-((1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)methoxy)ethyl)2-methoxy-4-nitrobenzonitrile. Prepared using the procedure described for 1,3-
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dimethyl-7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1H-purine-2,6(3H,7H)dione, using the corresponding chloro-acetal derivative. 1H NMR (400 MHz, CDCl3) δ
7.83 (s, 1H), 7.73 (s, 1H), 7.49 (s, 1H), 5.63, 5.59 (ABq, JAB = 11.2 Hz, 2H), 5.25 (q, J =
6.3 Hz, 1H), 4.00 (s, 3H), 3.56 (s, 3H), 3.35 (s, 3H), 1.49 (d, J = 6.3 Hz, 3H). 13C NMR
(101 MHz, CDCl3) δ 160.33, 155.27, 151.44, 150.90, 148.74, 142.11, 133.50, 131.89,
114.31, 107.12, 106.98, 106.66, 73.73, 72.48, 57.08, 29.95, 28.10, 23.82.
7-((1-(4,5-bis(2-(2-methoxyethoxy)ethoxy)-2-nitrophenyl)ethoxy)methyl)-1,3dimethyl-1H-purine-2,6(3H,7H)-dione. Prepared using the procedure described for 1,3dimethyl-7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1H-purine-2,6(3H,7H)dione, using the corresponding chloro-acetal derivative. 1H NMR (400 MHz, CDCl3) δ
7.66 (s, 1H), 7.51 (s, 1H), 6.96 (s, 1H), 5.71, 5.55 (ABq, JAB = 11.0 Hz, 2H), 5.44 (q, J =
6.2 Hz, 1H), 4.26 – 4.11 (m, 4H), 3.93 – 3.84 (m, 4H), 3.76 – 3.69 (m, 4H), 3.60 – 3.53
(m, 4H), 3.51 (s, 3H), 3.38 (s, 6H), 3.33 (s, 3H), 1.48 (d, J = 6.3 Hz, 3H). 13C NMR (101
MHz, CDCl3) δ 155.04, 153.36, 151.48, 148.61, 147.50, 141.77, 140.13, 134.30, 109.78,
109.75, 109.29, 74.58, 73.86, 72.06, 70.98, 69.53, 69.41, 69.15, 68.83, 59.17, 29.82,
28.05, 23.80.
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Figure 13. TheoRS-hapR-mKate construct in V.c.

Figure 14. Photolysis of new nitrile photocage
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Figure 15. Photolysis of bis-PEG analog

Figure 16. Synthesis of caged-theophylline
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Chapter 3
Gem-dinitro enols: Discovery and application of a new reaction for methyl ketones
Introduction
Due to the promising results of the nitrile-containing ONB photocage, additional
efforts were focused on optimizing the synthesis of this compound. The original synthetic
route employed a nucleophilic aromatic substitution on 1-(6-nitrobenzo[d][1,3]dioxol-5yl)ethanol and suffered from a low yield (<30%) and a difficult workup/purification.
Accordingly, a new substrate was identified and purchased in an attempt to improve both
the yield and overall efficiency of the route. This starting material, 1-(3-fluoro-4methoxyphenyl)ethanone, was superior in regard to possessing a better leaving group,
being a fluorine atom rather than a methylene dioxy group, and also already had the
methoxy substituent that was required for the final compound, thus eliminating the
methylation of the phenol step.
A major assumption that this new substrate depended on was that the first step of
the route, an aromatic nitration, would be selective and high yielding to the extent that it
was for the original methylene dioxy substrate. Upon performing a nitration on the fluoro
substrate however, it was observed that nitration of the ring did not occur. While all three
aromatic hydrogen atoms were accounted for by H1 NMR, the hydrogens on the alpha
carbon of the methyl ketone were absent. At this point in time this unknown product was
assumed to be the carboxylic acid, although this idea was not fully consistent with the
polarity and solubility of this compound, which seemed to be much less polar than the
acid would likely be.
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Several reactions and publications were identified after an in-depth search for
similar types of C-C bond cleavage reactions. The haloform reaction was discovered by
Adolf Lieben in 1870, although its history goes back a bit further to 18221. Employing
successive halogenation of an alpha carbon under basic conditions, the reaction is used to
produce carboxylic acids from methyl ketones, with a trihalomethane serving as a leaving
group. Similar to this, for our reaction we envisioned nitration of an alpha carbon
resulting with either mono/di/tri-nitromethane acting as a leaving group. Some precedent
exists for the transformation of mono alpha-nitro methyl ketones into esters and amides
from Sarma et al and Ballini et al2,3. After review of these publications, it seemed unlikely
that the mechanism of our reaction proceeded through the same mono-nitro ketone
intermediate, due to differences in conditions and substrate scope. An additional paper
was found regarding the conversion of methyl ketones in esters via an oxidative
mechanism using CuO2 that provided another example of this type of reaction, but also
likely differs in mechanism from ours4.
Results and Discussion
Isolation of key intermediates leads to the elucidation of the reaction
mechanism. A key possibility that was being explored in regard to mechanism included
mono, di and tri nitration of the alpha carbon, leading to mono, di or tri-nitro methane
serving as the leaving group. While precedent existed for the conversion of alpha mononitro ketones to amides, the conditions for this reaction were significantly different and
harsher than those for our reaction. Additionally, these alpha mono-nitro ketones were
commercially available and thus stable enough to isolate. Through dozens of reactions
and purifications, I had not isolated or observed any of these compounds, which are
easily identified by a singlet around 5-6 ppm in H1 NMR. In the case of alpha gem-di and
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tri-nitro ketones, little to no precedent exists in the literature which gave us doubts that
either of these were the intermediate that we have been looking for.
During the course of exploring the nucleophile substrate scope for para-bromo
acetophenone, an unknown molecule was obtained from a purification as a minor
byproduct, although in high purity. This compound looked like the corresponding
carboxlyic acid by H1 NMR, having the four hydrogen atoms in the aromatic ring but
lacking the three hydrogens of the methyl. A C13 NMR, on the other hand, suggested that
this mystery product was not the carboxylic acid, as it did indeed still have the carbon of
the methyl (in addition to the carbonyl carbon). Based off of the specific locations of the
peaks in the C13 NMR it was determined that this sample was the gem-di nitro
intermediate that was previously hypothesized. Given both the H1 and C13 NMR data, it
appears that this ketone derivative exists entirely in the enol form. This idea is consistent
with the lack of one hydrogen in the H1 NMR and the location of the carbonyl carbon in
the C13 NMR, being around 180 ppm rather than 200.
To further demonstrate that this compound was in fact the gem-di nitro enol and
also a competent intermediate, I subjected the molecule to a reaction with an amine in
attempt to produce an amide. Surprisingly, two distinct products were isolated after a
purification in similar amounts, both of which could be characterized by NMR. As we
had hoped, the desired amide product was indeed isolated, providing support for the
proposed intermediate. The other isolated product strongly resembled the amide product
by H1 NMR, with the exception that the two sets of doublets (arising from the 1,4disubstituted benzene ring) were shifted to a much higher ppm. C13 NMR spectra for this
unknown product did not have a carbonyl or enol peak present, but did have two peaks
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around 150 ppm (one of which belonging to the carbon of the dinitromethane). This shift
is consistent with an enamine carbon, which in fact is a plausible secondary intermediate
that could form after the gem-dinitro enol reacts with an NH-nucleophile. Similarly in the
case of the enol, the enamine tautotomer seems to preferred over the imine when the
alpha carbon is dinitro substituted.
While we did not necessarily expect to be able to isolate and purifiy intermediates
of this type, this breakthrough does suggest that these gem-dinitro enols and enamines are
stable to some degree. Still, more work needs to be done in order to obtain a more
complete understanding of the stability and reactivity of these currently unreported
intermediates.
Nucleophile substrate scope is wide-ranging. The first nucleophile tested in the
reaction was hydroxide, thus generating a carboxylic acid from 4-bromoacetophenone.
Due to the inherent difficulties in isolating and purifying acids, I shifted my focus on
attempting to produce the methyl ester of 4-bromoacetophenone (using methanol rather
than hydroxide as the nucleophile). This reaction proceeded smoothly, providing a
product that was both easier to isolate and purify than the carboxlic acid, and in higher
yield (81.0% yield instead of 69.6%). Two additional esters were then synthesized, a
benzyl and phenyl ester, using benzyl alcohol and phenol, respectively. While these
nucleophiles resulted in slightly lower yields than the methanol, the desired ester was
indeed produced, demonstrating some substrate inclusiveness for -OH nucleophiles.
Next I turned my attention to -NH nucleophiles in hopes of forming amides from
the methyl ketone of 4-bromoacetophenone. The first amine substrate that was attempted
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was 1-butylamine, which produced the corresponding amide in high yield (80.8%). After
that initial success several other amines were subjected to the reaction, and amides were
synthesized from benzyl amine, aniline, piperidine, N,O-dimethyl hydroxylamine, and
oxazolidinone. Yields from this series followed a general trend based on expected
nucleophilicity; primary amines were better than secondary and poor nucleophiles such
as aniline and oxazolidinone produced lower yields. Based off of these six amines, it
appears that substrate universality also exists for -NH nucleophiles in this reaction, most
of which proceed in moderate to high yields.
In addition to this list of -OH and -NH nucleophiles, a -SH nucleophile was tested
in order to produce a thioester. Thiophenol was employed for this purpose, however the
desired product was not isolated after several trials and purifications. The major
compounds obtained seemed to be the disulfide of thiophenol and another species that
could not be characterized. Ultimately, a different thiol (aliphatic) should be tested before
concluding that the thioeseters are not able to be produced from the reaction.
Ketone substrate scope includes both aromatic and alkyl methyl ketones.
Following the realization of the nucleophile substrate class, I turned my attention to
investigating the scope of ketone substrates. Based off of the success using 4bromoaceotophenone, other acetophenone derivates were the first to be tested. It become
apparent almost immediately, however, that many aromatic ketones would not be
competent in the reaction. For instance, in the case of acetophenone, para-methoxy
acetophenone and ortho-hydroxy acetophenone, nitrations of the aromatic ring were
observed thus inhibiting the desired nitration reaction from occuring. Heterocyclic methyl
ketones followed the same trend, as substrates containing pyridine, pyrrole, indole,
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thiophene and benzothiophene did not produce any desired product. In general, electronrich aromatics and heteroaromatics appear to be non-ideal for this reaction, as many of
these substrates will preferably undergo aromatic nitration rather than alpha nitration.
With this limitation in mind, I focused on identifying new aromatic methyl ketone
substrates in order to demonstrate that the reaction does not only work for 4-bromo
acetophenone. Accordingly, I performed bromination reactions on the substrates that
failed, and was able to isolate and purify several mono-bromo products. After subjecting
these news compounds to my reaction it was found that the desired amide was produced
in many cases. For example, 1-(3-bromo-4-methylphenyl)ethanone and 1-(3,4dibromophenyl)ethanone participated in the reaction and produced amides in good yields.
Interestingly, in the case of 1-(3-bromo-4-methoxyphenyl)ethanone, while the compound
did not nitrate the ring and thus did indeed generate the gem-dinitro enol, addition of an NH nucleophile and subsequent stirring overnight did not produce the amide as expected.
This observation potentially clues us into the affect of the substituent that is para to the
ketone, as the para methoxy allows the alpha nitration to occur but not the nucleophilic
substitution. Since alpha nitration occurs in the enol form, while the substitution reaction
occurs in the keto form, it can be hypothesized that an electron-donating substituent at the
para position stabilizes the enol form during the reaction. Ultimately, more aromatic
substrates need to be tested to confirm this trend and also to demonstrate better substrate
inclusiveness for acetophenones.
Next I became interested in testing aliphatic ketones in the reaction, since these
would in theory not be hindered by the side reactions seen in the aromatic substrates.
Pinacolone became the first aliphatic methyl ketone subjected to the reaction and was
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shown to be competent in the reaction, producing an amide in 58.4% yield. Acetone, on
the other hand, also worked but with much lower yield. This disparity could be due in
part to the keto/enol ratio for pinacolone and acetone, as pinacolone would supposedly
have lower yield due to the steric hindrance around the carbonyl carbon from the tert
butyl group. Nonetheless, these two examples provide good support for the claim that the
reaction works for aliphatic methyl ketones and not just aromatic substrates.
Another alkyl methyl ketone substrate that was tested was 4-(4-nitrophenyl)butan2-one, which produced a very peculiar result. In addition to the desired amide product
that was obtained in about 25% yield, an unknown compound was isolated from
purification that appeared to have the para nitro-substituted benzene ring but was missing
the rest of the structure. It was unable to be determined what the other substituent on the
1,4 disubstituted benzene was or how aromatic dealkyation took place. This remains an
area of interest that could potentially lead to a side project after this work gets published,
but further investigation of this strange result is not a priority.
Application of this new reaction to produce medicinally relevant
compounds. In order to further validate the usefulness of this new reaction, I next
utilized it to synthesize pharmaceutically pertinent moieties. Using ortho-phenyllene
diamine as the nucleophile and heating the reaction overnight, I was able to obtain a
benzimidazole from 4-bromoacetophenone in moderate yield. Benzimidazoles are
important heterocycles found in a variety of drugs and are almost exclusively synthesized
from carboxlic acids or aldehydes. Generation of these molecules from methyl ketones is
far less common, with only a small number of procedures existing for this transformation.
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For that reason, this has the potential to become a separate publication, pending further
investigations regarding substrate scope and practicality.
Another class of biologically relevant compounds that can be produced from this
reaction are methyl ketone-containing steroids such as progesterone derivatives. Since
several semi-synthetic steroids are/were availabe as drugs, this one-step transformation
from progesterone could provide an assortment of amide and ester analogs with unique
properties and applications. A reaction with benzyl amine demonstrated that this substrate
was able to participate in the dinitro enol reaction, but the yield is currently not known.
At any rate, the fact progesterone is cheap and widely available makes the one-step
process worthwhile even if yields are moderately low.
Conclusion
A new reaction for methyl ketones provides carboxylic acids, esters and amides
from a simple one-pot procedure. A large variety of -NH and -OH nucleophiles are
tolerated, and both aromatic and aliphatic methyl ketones have been demonstrated to
participate in the reaction. Through the isolation of previously unreported intermediates,
a plausible mechanism has been suggested involving gem-dinitro enols that are formed
via alpha-nitration of a methyl ketone. The reaction has great potential to be employed
for the synthesis of biologically active compounds such as benzimidazoles and steroid
derivatives. Currently, this work is being concluded and will be submitted for publication
in due time.
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Figure 17. Reaction scheme and examples of nucleophile substrate scope

Figure 18. Proposed reaction mechanism
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Experimental Section
General chemistry. All reagents and solvents were obtained from commercial
sources and used without further purification or drying. Reactions were performed under
a nitrogen gas atmosphere in flame-dried glassware. Unless otherwise noted, compounds
were not purified. 1H and 13C NMR data was taken on a Varian AS400 (400 MHz), with
chemical shifts being displayed in a ppm scale referenced to residual chloroform.
4-bromobenzoic acid. 4-bromoacetophenone (139.3 mg, 0.700 mmol) was
dissolved in ACN (1.4 mL, 0.5 M) and cooled to 0 ºC. Acetic anhydride (0.20 mL, 3.0
EQ, 3.58 M) was added, followed by 90% nitric acid dropwise (0.20 mL, 6.0 EQ, 3.58
M). The solution was allowed to warm to room temperature and stir overnight. After
cooling to 0 ºC, the reaction was quenched with DIPEA dropwise (12 EQ). KOH (19.6
mg, 0.5 EQ) was added and the mixture was allowed to stir at room temperature
overnight. The product was isolated after standard workup and purified by silica-gel
column chromatography, affording 96.7 mg of the desired product, 69.6% yield.
Methyl 4-bromobenzoate. Prepared using the procedure described for 4bromobenzoic acid, using the corresponding nucleophile (methanol), 81.0% yield.
Phenyl 4-bromobenzoate. Prepared using the procedure described for 4bromobenzoic acid, using the corresponding nucleophile (phenol), 64.0% yield.
Benzyl 4-bromobenzoate. Prepared using the procedure described for 4bromobenzoic acid, using the corresponding nucleophile (benzyl alcohol), 55.8% yield.
4-bromo-N-butylbenzamide. Prepared using the procedure described for 4bromobenzoic acid, using the corresponding nucleophile (1-butyl amine), 80.8% yield.
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N-benzyl-4-bromobenzamide. Prepared using the procedure described for 4bromobenzoic acid, using the corresponding nucleophile (benzyl amine), 79.4% yield.
(4-bromophenyl)(piperidin-1-yl)methanone. Prepared using the procedure
described for 4-bromobenzoic acid, using the corresponding nucleophile (piperidine),
59.3% yield.
4-bromo-N-methoxy-N-methylbenzamide. Prepared using the procedure
described for 4-bromobenzoic acid, using the corresponding nucleophile (N,O dimethyl
hydroxylamine HCl), 77.7% yield.
4-bromo-N-phenylbenzamide. Prepared using the procedure described for 4bromobenzoic acid, using the corresponding nucleophile (aniline), 40.3% yield.
3-(4-bromobenzoyl)oxazolidin-2-one. Prepared using the procedure described
for 4-bromobenzoic acid, using the corresponding nucleophile (oxazolidinone), 11.1%
yield.
2-(4-bromophenyl)-1H-benzo[d]imidazole. Prepared using the procedure
described for 4-bromobenzoic acid, using the corresponding nucleophile (orthophenyllene diamine), 35.4% yield.
N-benzylpivalamide. Prepared using the procedure described for N-benzyl-4bromobenzamide, using the corresponding ketone (pinocolone), 58.4% yield.
N-butyl-3-(4-nitrophenyl)propanamide. Prepared using the procedure described
for 4-bromo-N-butylbenzamide, using the corresponding ketone, 25.3% yield.
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92

Phenyl 4-bromobenzoate
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Benzyl 4-bromobenzoate

94

4-bromo-N-butylbenzamide

95

N-benzyl-4-bromobenzamide

96

(4-bromophenyl)(piperidin-1-yl)methanone

97

4-bromo-N-methoxy-N-methylbenzamide

98

4-bromo-N-phenylbenzamide

99

3-(4-bromobenzoyl)oxazolidin-2-one

100

2-(4-bromophenyl)-1H-benzo[d]imidazole

101

N-benzylpivalamide

102

N-butyl-3-(4-nitrophenyl)propanamide

103

1-(4-bromophenyl)-2,2-dinitroethenol
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N-(1-(4-bromophenyl)-2,2-dinitrovinyl)butan-1-amine
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Chapter 4
Structure-activity relationship of a triphenyl scaffold for the LasR receptor in
Pseudomonas aeruginosa
Introduction
Due to the array of medically relevant cellular processes that are under the control
of LuxR-type quorum sensing circuits, significant effort has been directed toward the
identification of antagonist molecules in several different bacterial pathogens1-3. These
efforts have led to the identification of antagonists from natural sources4, diversityoriented compound libraries5-6, and focused library synthesis7-8. The most broadly
explored class of LuxR-type receptor antagonists are based on the structural features
found in the native HSLs, maintaining the homoserine lactone while changing the
functionality of the acyl-tail. Some initial attempts to inhibit HSL-mediated quorum
sensing in Gram-negative bacteria have yielded promising results. In studies of P.
aeruginosa,9 a significant bacterial pathogen associated with cystic fibrosis lung
infection, bacterial keratitis (eye infection), and third degree burn associated skin
infections, several antagonists have been identified that inhibit the HSL receptor, LasR1012

.
A major obstacle that remains in the development of an anti-quorum sensing

strategy targeting LasR and other LuxR-type receptors is ligand potency10. The high
levels of affinity and specificity that the receptor displays for its native HSL ligand
complicates this challenge. As the result, studies of antagonism (inhibition) are typically
performed using synthase mutants where the native autoinducer is added exogenously at
minimal concentrations. The approach of using synthase mutants with minimal
concentrations of the quorum sensing agonist provides valuable information

106

about

antagonism of LuxR-type receptors but is misleading in terms of potency as the systems
studied are often not representative of wild-type bacteria. Strategies to overcome the
limitation of inhibitor potency are expected to be significant in the development of antiquorum sensing therapeutics. Further, many of the inhibitors that have been identified
maintain the physiologically labile homoserine lactone functionality, limiting the
potential of these antagonists for development as therapeutic agents.
The inhibition of quorum sensing with small molecules offers a unique strategy
for the treatment and prevention of a number of acute and chronic bacterial infections, a
fact that is of particular significance given the rapid and ongoing spread of antimicrobialresistant bacteria2,13,14. Research in this area has been defined as a Category C Priority by
the NIAID15. Through the inhibition of quorum sensing, control over expression of
virulence factors and biofilm formation is achieved, rendering the bacteria benign while
not directly affecting viability. This anti-infective approach is conceptually distinct from
traditional approaches for the treatment of bacterial infection that typically utilize
bactericidal or bacteriostatic molecules, targeting critical cellular processes. As
exemplified by the spread of bacterial resistance, these treatments provide a considerable
growth advantage to bacteria that can resist the drug. Contrasting this approach, the
inhibition of quorum sensing does not affect cellular viability, decreasing the growth
advantage of resistance16. Rather, this approach targets cellular signaling, inhibiting the
expression of virulence factors necessary for successful infection, rendering the bacteria
benign until the hosts immune system can clear the pathogen2,17-19.
Recently a highly potent activator of quorum-sensing in P. aeruginosa was
identified from a high-throughput screen (2, Figure 2)2. While the activation of virulence
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factor expression in this bacterial pathogen is not therapeutically desirable our rationale
to obtain the desired inhibitory function for this potent agonist through analog synthesis
is based on precedent. Most notably, a large number of inhibitors have been discovered
by systematic modification of HSLs, molecules which serve as natural QS activators. The
agonist discovered (2) bears many structural and pharmacological properties that make it
superior to HSLs as a lead compound for the development of an anti-virulence therapy,
including the absence of a metabolically labile homoserine lactone. Additionally, the
potency of this molecule for activation of LasR exceeds the potency of the natural
signaling molecule and compounds of this structure type have never been systematically
analyzed for the effect of their structure-activity relationships (SARs)5-20. Accordingly,
our goal is to take advantage of the high potency and the more desirable pharmacological
properties of this lead compound and optimize the structure to possess the function that
we desire, the inhibition of virulence.
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Figure 19. A) Detail of the crystal structure of 3-oxo-C12-HSL (PDB 3IX3) and 2 complexed
to LasR (PDB 3IX4). B) Two scaffolds targeted for library synthesis and structure-activity
relationship studies. C) Modular chemical synthesis pathways for library assembly.
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Results and Discussion
Synthesis. Challenging our efforts toward the goal of identifying inhibitors of
LasR based on the structure of 2 is the number of synthetic steps required for its assembly
(Figure 2B). To prepare a library of molecules related to 2 requires a more efficient
synthetic route. Identification of an effective approach to the synthesis of our target
molecules was informed by examination of the recently published crystal structure of the
QS receptor in P. aeruginosa, LasR, in the presence of 221. Analysis of the binding
pocket for the ligand suggested that a subtle structural change in the orientation of the
amide bond in 2 (Figure 2B, highlighted in red) may be tolerated.

Based on these target scaffolds, we have successfully identified two efficient and
modular synthetic routes to analogs containing the core scaffold as in 2 (Scaffold #1)
analogs containing the core scaffold as in 3 (Scaffold #2) We have begun to
systematically optimize the structural features of the targeted molecules to modify the
potency and the function of this class of potential anti-virulence therapeutic agents. To
date we have prepared and evaluated the biological activity of more than 50 analogs of 2
and 3. These efforts will be discussed in greater detail below and additional analogs will
be prepared to support and expand on our preliminary findings during the timeframe of
this proposal.
Analysis of the crystal structure of LasR complexed to 221 suggests that the two
terminal aromatic rings (Figure 2B, labeled “A” and “C”) play an important role by
interacting with LasR whereas the central ring appears to play primarily a scaffolding
role in ligand binding. Therefore, we have focused our initial efforts on identifying the
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structure activity correlations of the pendant ring structures (“A-ring” and “C-ring”)
while maintaining the structure of the central ring (“B-ring”). While the two scaffolds
differ only in the orientation of one amide bond, we have observed some notable
differences in biological activity for analogs prepared on the two different scaffolds
which will be discussed further below.
“A-ring” Structure Activity Relationship Studies. To validate our systematic
strategy for optimization of the biological properties of 3, a small library of structural
analogs were prepared. Reaction of intermediate 7 (Figure 2) with a series of structurally
related acid chlorides (analogous to 8) provided library of “A-ring” analogs (Table 1).
From this series of structural analogs, we observe a consistent dependence of substitution
in this ring structure on the potency of the molecules. We discovered that substitution in
the ortho-position of the arene (entries 1, 4, 7, 9, 10, and 13-15) is critical for potency.
Substitution in the meta- or para-position of the “A-ring” (entries 2-3, 5-7 and 11-12)
leads to the complete loss of potency as measured by comparing the EC50 values of the
compounds determined using the bacterial reporter strain described earlier. In support of
the significance of ortho-substitution, an analog was prepared containing chlorine atoms
at both of the ortho-positions of the “A-ring” (entry 16) increasing the potency of this
LasR agonist. Interestingly, the activity of the analogs bearing ortho-substitution appears
to be largely independent of the nature of the substituent. Analogs with electonwithdrawing substituents (halogen, nitro, trifluoromethyl) and electron-donating groups
(methyl, methoxy) in the ortho-position all are agonists with EC50 values between 0.1 and
1.3 uM. Generally we find that analogs with substituents in the ortho-position are potent
agonists whereas the meta- or para-substituted analogs are universally not active. This
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may suggest that the binding pocket in LasR for this portion of the molecule is not able to
accommodate substituents in either the meta- or para-position. Further, the comparable
activities of the analogs containing electronically and sterically diverse substituents in the
ortho-position suggests that this substitution does not have a direct role interacting with
the receptor (no specific hydrogen-bonding or electronic interactions with the receptor)
but rather may simply play an anchoring role for the overall positioning of the “A-ring”.
In support of this hypothesis, we have found that while the nature of the substituent in the
ortho-position does not lead to significant changes in potency (EC50) or function (most
are agonists) the absence of an ortho-substituent results in the complete loss of activity.
Entry 18, in which the “A-ring” bears no substitution is completely inactive.
“C-ring” Structure Activity Relationship Series. While most analogs that we
have analyzed with changes in the structure of the “A-ring” were found to be either
agonists or to have no activity (i.e. changes in potency), analogs with structural changes
in the “C-ring” (Table 2) have both changes in potency and changes in function (agonism
vs. antagonism). We first assessed the impact of the position of the nitro-substituent on
the activity of the molecules (entries 1-3), revealing the necessity of an ortho-nitro
substituent. We then prepared a series of analogs in which the ortho-nitro group on the
“C-ring” of the parent compound (3) was exchanged for functionality that had been
previously found to be a suitable bioisostere of an aromatic nitro group22. While the 2pyridine was observed to have no agonist activity (entry 4) the di-fluoro bioisostere was
found to show enhanced activity as a LasR agonist (entry 5). Introducing additional
electron-withdrawing substituents onto the ring (entry 6) had minimal effect on activity
however, interestingly, the pyrimidine analog (entry 7) was found to be active as an
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agonist. Combining the 2-nitro substitution with a ring nitrogen at the 4-position (entry 8)
also provided an agonist of comparable activity to the parent compound. Therefore within
the series of aromatic and heteroaromatic analogs of this ring highest agonist activity was
noted with the di-fluoro analog (entry 5) and the 2-pyridine and meta- and para-nitro
analogs were found to be inactive. Based on published crystal-structure analysis from
which the ortho-nitro ring serves the role of a mimic of the homoserine lactone
characteristic of this class of signaling molecules, we replaced this ring with a
homoserine lactone. Notably, this analog (entry 10) displays significantly enhanced
potency to the natural LasR signaling molecule, 3-oxo-C12-HSL, with an EC50 value of
0.9 nM.
We next turned our attention to evaluating the structure-activity relationships
surrounding changes to the amide bond linking the “C-ring” to the “B-ring” (Table 3).
While we found that converting the amide bond into a benzimidzole linker (entry 2)
provided an analog with no activity, several sulfonamides we prepared showed potent
agonist activity (entries 5 and 6), successfully serving as structural mimics for the amide
bond found in the parent compound.
We next turned our attention to evaluation of the role of the orientation of the
amide bond linking the “B-ring” and the “C-ring” on the activity of several of the “Cring” analogs prepared. We selected the new 2-pyridine, di-fluoro and pyrimidine “Cring” analogs for this analysis as these analogs displayed a range of agonist activities in
our initial library. Therefore, we prepared analogs XX-XX and evaluated them for both
their agonist and antagonist activity in the LasR quorum sensing reporter strain (Figure
2). In our analysis, we found that 2-pyridine analog XX, earlier observed to show no
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agonist activity against LasR (Table 2, entry 4) possessed potent antagonist activity with
an IC50 of 42uM. The potency of this inhibitor of LasR compares favorably with the “best
in class” inhibitors of this quorum sensing circuit and represents one of the most potent
inhibitors discovered6-8,23-26. We additionally prepared this analog with the amide linker
between the “B-ring” and the “C-ring” reversed and observed that this analog (XX) had
similarly low LasR agonist and high LasR antagonist activity to XX. We next prepared
an analog containing a reversed amide corresponding to the potent difluoro arene full
LasR agonist XX (EC50 = 46nM). To our surprise, this analog (XX) was not an agonist of
LasR, instead it displayed a change in function, instead acting as an antagonist of LasR
QS with an IC50 of 65uM (80% maximal inhibition). In contrast to this finding, when we
prepared the reversed amide analog of the weak agonist pyrimidine XX (EC50 = 0.6uM)
we found the new analog (XX) to similarly be a weak agonist of LasR with an EC50 of
1.3uM.
Given the antagonist activity of the pyridine analog and our previous success with
the design of irreversible inhibitors of LasR we evaluated a series of chloropyridines and
electron poor arenes as potential irreversible antagoinsts of LasR (Table 3). While we
found two analogs with potent antagonist activity (entries 1,2 and 4) these analogs do not
appear to be irreversible inhibitors of LasR based on competition binding assays with the
native agonist 3-oxo-C12HSL. While the mechanism of inhibition does not appear to
require irreversible attachment to LasR, we note that only analogs containing a chlorine
ortho to the ester linker showed activity as antagonists. Entry 3, which only has a
chlorine meta to the ester linkage showed no activity in our assay.
In an effort to enhance the potency of the series of irreversible
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maleimide

containing LasR antagoinsts we had previously identified we prepared two targeted
inhibitors combining structural changes in the “C-ring” with the appropriate chain-length
tether to a maleimide in place of the “A-ring” based on our previous studies. For this
investigation we selected the most potent “C-ring” LasR antagonist analog on the
reversed amide backbone (amide as in TP-1, 2) and the most potent “C-ring” LasR
agonist analog on the amide backbone as in 3. We rationalized that we might enhance the
antagonist activity of the 2-pyridine analog (XX, Figure 2) by combining this feature with
the appropriately positioned maleimide for irreversible modification of a conserved
cysteine in the LasR ligand binding pocket. In the event, the designed analog XX
underperformed our expectations, showing antagonist activity however with an increased
IC50 value (116uM with 2-pyridine vs. 1.5uM with the 2-nitro analog). We next prepared
an analog containing the HSL headgroup as the “C-ring” structure based on an analog
which we had observed to provide significant agonist activity against LasR (Table 2,
entry 10). We rationalized that if the more potent EC50 observed this “C-ring” analog was
attributed to a lower KD, then combining this enhanced binding of the analog effect with
the introduction of a maleimide appropriately positioned to irreversibly react with LasR
should provide enhanced antagonist activity. In the analysis, the designed analog XX did
indeed demonstrate potent antagonist activity (IC50 = 13.1uM). This analog represents
one of the most potent antagonists if LasR discovered being comparable to the “best in
class” potency we had previously identified for analog XX.
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Table 1. Structure-activity relationships of “A-ring” analogs.

Entry

Structure

EC50 (nM)

% Max

Entry

1

371.6±40.7

105

2

<5000

3

EC50 (nM)

% Max

10

757.4±653

85

0

11

<5000

24

<5000

0

12

<5000

33

4

271.4±21.5

82

13

246.5±122

45

5

<5000

44

14

489.0±1,280

37

6

<5000

35

15

350.4±138

64

7

1,287±598

76

16

312.6±149

95

8

<5000

39

17

161.3±101

56

116

Structure

9

157.8±45.6

50

18

<5000

0

EC50 (nM)

%
Max

Table 2. Structure-activity relationships of “C-ring” analogs.

EC50 (nM)

%
Max

Entry

1

371±40.7

105

6

335±194

89

2

<5000

0

7

601±464

92

3

<5000

0

8

446±257

112

4

<5000

0

9

<5000

0

5

45.6±2.8

116

10

0.896±2.1

105

Entry

Structure
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Structure

Table 3. Structure-activity relationships of alternative linkers.

EC50
(nM)

%
Max

Entry

1

371±40.7

105

2

<5000

3

xxx

Entry

Structure

EC50 (nM)

%
Max

4

<5000

0

0

5

25.2±15.2

77

xxx

6

183±48

72

IC50 (μM)

%
Max

Structure

Table 4. Chloropyridine analogs as antagonists of LasR.

IC50 (μM)

%
Max

Entry

1

7.89±8.5

94

3

<100

50

2

33.9±39

107

4

65.0±110

124

Entry

Structure

118

Structure

Figure 20. Effect of amide bond configuration and identification of potent LasR
antagonists.

Figure 21. Hybrid analogs combining optimized structural features identified in this
study with a maleimide for LasR irreversible inhibition.
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Conclusion
We have evaluated a series of synthetic libraries of non-natural modulators of
LasR-mediated QS in Pseusomonas aeruginosa. The compounds prepared are significant
as they represent a novel drug-like scaffold for the preparation of inhibitors of bacterial
virulence. We have identified several notable stricture-activity relationships and in so
doing have paved the way for the rational design of potent inhibitors of LasR QS. We
have demonstrated several series of analogs which possess the therapeutically desirable
LasR antagonist activity and have defined structural features which contribute positively
to both this desirable function of the ligands evaluated while simultaneously
characterizing structural features which positively contribute to the potency of the
molecules tested.
While I did not prepare all of the compounds presented in this Chapter, I have
played an active role in this project since its inception. The summary of our progress
described here represents a collaborative effort and I am grateful for the contributions of
my co-workers in the Perez group who have worked with me on this project. During the
time-period of my Masters thesis research not only did I personally prepare a large
percentage of the molecules to complete the analysis described above but I additionally
played an active role designing targets, training and trouble-shooting synthetic challenges
faced by my co-workers in this project. Therefore, here I present a comprehensive
overview of the progress we have made in this area.
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Experimental Section
Bacterial reporter strain assay. Our collaborator Prof. Ng developed the
biological assay for this project. A reporter strain was first produced using V. cholera in
which the expression of a luminescent protein is controlled by Hfq-sRNA. For practical
purposes, an increase in luminescence (or Lux/OD600) corresponds to an increase in
inhibition of the Hfq-Qrr complex, whereas compounds that do not effect this proteinRNA interaction do not generate luminescence. To prepare for the assay, an overnight
culture of the V. cholera reporter strain was incubated at 30 °C in LB media containing
100 µg/mL of Kanamycin and 5 µg/mL of Tetracyclin. Following a 1:50 dilution of this
culture into the same LB media, 175 µL was placed into each well of a clear bottom 96well plate. Next, 10.5 µL of a 10 mM solution of each compound in DMSO was added in
triplicate to the wells in the first column. A 2.4 fold dilution was then performed by
transferring 125 µL from the first column to the next, and repeating this down the entire
plate. Plates were incubated at 30 °C and luminescence (Lux) and OD600 were read at 4, 5
and 6 hours. Dose response curves were generated using Prism software, and were
plotted as Lux/OD600 vs. log[conc.].
General chemistry. All reagents and solvents were obtained from commercial
sources and used without further purification or drying. Reactions were performed under
a nitrogen gas atmosphere in flame-dried glassware. Unless otherwise noted, compounds
were not purified. 1H and 13C NMR data was taken on a Varian AS400 (400 MHz), with
chemical shifts being displayed in a ppm scale referenced to residual chloroform.
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3,5-dibromo-2-hydroxybenzamide. Salicylamide (10.0 g, 72.9 mmol) was
dissolved in glacial acetic acid (146 mL, 0.5 M) and Br2 (11.2 mL, 218.7 mmol) was
added dropwise. The reaction stirred overnight at room temperature and then was
quenched with water (500 mL). Product was filtered and washed with a small amount of
water and then dried in a dessicator, affording 20.2 g of the desired product, which was
used crude in the subsequent step, 93.5% yield.
2-(benzyloxy)-3,5-dibromobenzamide. 3,5-dibromo-2-hydroxybenzamide (10.0
g, 33.7 mmol) was dissolved in acetone (337 mL, 0.1 M) and K2CO3 (5.58 g, 40.4 mmol)
was added, followed by benzyl bromide (4.80 mL, 40.4 mmol) dropwise. The mixture
was stirred at reflux overnight and then was cooled to room temperature. Potassium
carbonate was filtered off (filtrate was washed with more acetone) and the solvent was
removed in vacuo. The product was recrystallized in acetone, affording 11.3 g of the
desired product, 87.1% yield.
(2-(benzyloxy)-3,5-dibromophenyl)methanamine. 2-(benzyloxy)-3,5dibromobenzamide (1.0 g, 2.58 mmol) was dissolved in BH3.THF (13.24 mL, 13.24
mmol) under N2 and the mixture was heated to reflux. The reaction stirred for 48 h at 75
°C and was monitored by TLC (10 mL additional BH3.THF was added at 30 h). Methanol
(10 mL x 2) was added dropwise to quench the reaction, and then the solvent was
removed in vacuo. The product was used crude in the subsequent step without
purification, quant. yield. 1H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 2.5 Hz, 1H),
7.91 (s, 1H), 7.74 (s, 1H), 7.60 (d, J = 2.4 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.40 – 7.29 (m,
3H), 4.95 (s, 2H), 4.36 (t, 2H). 13C NMR (101 MHz, DMSO-d6) δ 151.79, 136.32,
136.20, 134.68, 131.19, 128.40, 128.39, 119.03, 116.67, 60.79, 29.25.
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N-(2-(benzyloxy)-3,5-dibromobenzyl)-2-nitrobenzamide. 2-nitrobenzonic acid
(534.8 mg, 3.20 mmol) was dissolved in CH2Cl2 and the solution was cooled to 0 °C
under N2. Oxalyl chloride (0.550 mL, 6.40 mmol) was added dropwise, followed by
DMF (1 drop). The reaction was allowed to warm to room temperature as it stirred for 2
h. Solvent and excess oxalyl chloride was removed in vacuo and then the residue was
resuspended in CH2Cl2. This acid chloride was added dropwise to a solution of (2(benzyloxy)-3,5-dibromophenyl)methanamine (655 mg, 1.60 mmol) in CH2Cl2 (32 mL,
0.1 M). Triethylamine (1.56 mL, 11.2 mmol) was added, followed by DMAP (cat.) and
the mixture stirred overnight at room temperature. After quenching the reaction with
water (25 mL), more CH2Cl2 was added (50 mL) and the organic layer was washed with
HCl (50 mL, 1 M), sat. NaHCO3 (50 mL) and then brine (50 mL), and then was dried
over Na2SO4. Purification via silica-gel column chromatography (product elutes around
30% EtOAc) afforded 354 mg of the desired product, 42.5% yield. 1H NMR (400 MHz,
CDCl3) δ 8.04 (dd, 1H), 7.69 (d, J = 2.4 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.59 – 7.53 (m,
2H), 7.44 – 7.40 (m, 2H), 7.37 – 7.29 (m, 3H), 7.26 – 7.20 (m, 1H), 5.81 (t, J = 6.1 Hz,
1H), 5.05 (s, 2H), 4.46 (d, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 166.46,
153.03, 146.43, 136.07, 135.70, 134.99, 133.83, 132.54, 132.45, 130.73, 129.03, 128.89,
128.87, 128.75, 124.72, 118.29, 117.99, 75.85, 39.21.
N-(3,5-dibromo-2-hydroxybenzyl)-2-nitrobenzamide. N-(2-(benzyloxy)-3,5dibromobenzyl)-2-nitrobenzamide (354 mg, 0.681 mmol) was dissolved in CH2Cl2 (4.54
mL, 0.15 M) and cooled to -78 °C in a dry ice/acetone bath. BBr3 (65 µL, 0.681 mmol)
was added dropwise and the mixture stirred for 3 h while the temperature was kept
between -20 and -60 °C. The reaction was quenched with sat. NaHCO3 (25 mL) and was
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extracted with CH2Cl2 (50 mL). This organic layer was washed with brine and then dried
over Na2SO4. Purification via silica-gel column chromatography (product elutes around
40% EtOAc) afforded 129.5 mg of the desired product, 30.2% yield. 1H NMR (400 MHz,
DMSO-d6) δ 9.25 (t, J = 6.2 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H),
7.70 – 7.56 (m, 3H), 7.34 (d, J = 2.2 Hz, 1H), 4.37 (d, J = 5.1 Hz, 2H). 13C NMR (101
MHz, DMSO-d6) δ 166.33, 151.20, 147.18, 133.78, 133.02, 131.85, 131.14, 130.27,
130.03, 129.20, 124.28, 112.36, 110.97, 38.51.
2-(2-methoxyphenyl)-N-(2-nitrophenyl)acetamide. 2-methoxyphenyl acetic
acid (6.75 g, 40.62 mmol) and 2-nitroaniline (3.76 g, 27.07 mmol) were dissolved in
ACN (90 mL, 0.3 M). Thionyl chloride (2.86 mL, 40.62 mmol) was added dropwise and
the mixture stirred at reflux for 24 h. Solvent was removed in vacuo and the residue was
resuspended in EtOAc (150 mL) and washed with sat. NaHCO3 and then brine. After
drying over Na2SO4, the product was purified via silica-gel column chromatography
(product elutes around 30% EtOAc) affording 5.313 g of the desired product, 68.6%
yield. 1H NMR (400 MHz, CDCl3) δ 10.37 (s, 1H), 8.76 (dd, J = 8.6, 1.3 Hz, 1H), 8.12
(dd, J = 8.5, 1.6 Hz, 1H), 7.64 – 7.53 (m, 1H), 7.39 – 7.27 (m, 2H), 7.18 – 7.07 (m, 1H),
7.04 – 6.93 (m, 2H), 3.91 (s, 3H), 3.82 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 170.72,
157.24, 136.58, 135.73, 134.97, 131.43, 129.54, 125.65, 123.09, 122.45, 122.13, 121.19,
110.86, 55.50, 40.69.
2-(2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide. 2-(2-methoxyphenyl)-N-(2nitrophenyl)acetamide (6.927 g, 24.2 mmol) was dissolved in CH2Cl2 (161.3 mL, 0.15
M) and cooled to -78 °C in a dry ice/acetone bath. BBr3 (2.29 mL, 24.2 mmol) was added
dropwise and the mixture stirred for 4 h while the temperature was kept between -20 and
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-60 °C. The reaction was quenched with sat. NaHCO3 (100 mL) and was extracted with
more CH2Cl2 (100 mL). This organic layer was washed with brine and then dried over
Na2SO4. Purification via silica-gel column chromatography (product elutes around 40%
EtOAc) afforded 3.98 g of the desired product, 60.5% yield. 1H NMR (400 MHz, CDCl3)
δ 10.60 (s, 1H), 8.72 (dd, J = 8.6, 1.3 Hz, 1H), 8.16 (dd, J = 8.4, 1.6 Hz, 1H), 7.66 – 7.59
(m, 1H), 7.50 (s, 1H), 7.24 – 7.13 (m, 3H), 6.98 – 6.90 (m, 2H), 3.84 (s, 2H). 13C NMR
(101 MHz, CDCl3) δ 171.92, 154.90, 136.82, 136.01, 134.33, 131.33, 129.68, 125.84,
123.92, 122.63, 121.28, 120.58, 117.08, 41.86.
2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide. 2-(2hydroxyphenyl)-N-(2-nitrophenyl)acetamide (2.363 g, 8.68 mmol) was dissolved in
glacial acetic acid (173.6 mL, 0.05 M) and Br2 (1.33 mL, 26.0 mmol) was added
dropwise. The reaction stirred for 1 h at room temperature and then was quenched with
water (100 mL). The product was extracted with CH2Cl2 (50 mL x 3) and then the
combined organic layers were washed with sat. NaHCO3 and then brine, and then dried
over Na2SO4. Purification via silica-gel column chromatography (product elutes around
40% EtOAc) afforded 3.34 g of the desired product, 89.5% yield. 1H NMR (400 MHz,
CDCl3) δ 10.58 (s, 1H), 8.73 (dd, J = 8.5, 1.3 Hz, 1H), 8.19 (dd, J = 8.5, 1.6 Hz, 1H),
7.67 – 7.60 (m, 1H), 7.59 (d, J = 2.3 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.22 – 7.16 (m,
1H), 6.76 (s, 1H), 3.83 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 169.59, 150.37, 136.68,
136.12, 134.46, 134.19, 133.51, 125.93, 123.89, 123.42, 122.45, 113.01, 111.92, 41.18.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate. To 2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide (53.0
mg, 0.123 mmol) in CH2Cl2 (2.46 mL, 0.05 M) under N2 was added 2-chlorobenzoyl
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chloride (19 µL, 0.148 mmol), followed by Et3N (41 µL, 0.295 mmol) and then DMAP
(1.5 mg, 0.0123 mmol). The mixture was allowed to stir overnight at room temperature
and then was diluted with CH2Cl2 (50 mL) and washed with HCl (25 mL, 1 M), sat.
NaHCO3 (25 mL) and then brine (25 mL). After drying over Na2SO4, the material was
purified via silica-gel flash chromatography, affording XX mg of the desired product
(XX% yield). 1H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.67 (dd, J = 8.5, 1.1 Hz, 1H),
8.17-8.10 (m, 2H), 7.81 (d, J = 2.2 Hz, 1H), 7.63-7.56 (m, 2H), 7.50-7.45 (m, 2H), 7.367.30 (m, 1H), 7.16 (ddd, J = 8.5, 7.3, 1.3 Hz, 1H), 3.78 (s, 2H). 13C-NMR (125MHz,
CDCl3)  169.8, 162.2, 146.6, 136.6, 136.2, 135.9, 135.1, 134.5, 134.2, 133.8, 132.6,
131.7, 130.7, 127.6, 127.1, 125.9, 123.9, 122.4, 120.6, 118.9, 40.8.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.35 (s, 1H), 8.68 (d, J = 8.4 Hz,
1H), 8.15 (dd, J = 8.5, 1.3 Hz, 1H), 8.09-8.05 (m, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.79 (d, J
= 2.2Hz, 1H), 7.63 (ddd, J = 8.5, 7.2, 1.0 Hz, 1H), 7.60-7.54 (m, 2H), 7.39 (t, J = 7.9 Hz,
1H), 7.18 (ddd, J = 8.4, 7.3, 1.1 Hz, 1H), 3.71 (s, 2H). 13C-NMR (125MHz, CDCl3) 


167.8, 162.6, 146.6, 136.4, 136.3, 135.8, 135.2, 134.6, 134.5, 133.8, 130.8, 130.6, 130.3,
129.7, 128.8, 126.0, 123.9, 122.2, 120.6, 118.8, 41.0.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.67 (dd, J = 8.5, 1.1
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Hz, 1H), 8.15 (dd, J = 8.5, 1.5 Hz, 1H), 8.08-8.03 (m, 2H), 7.79 (d, J = 2.2 Hz, 1H), 7.62
(ddd, J = 8.6, 7.2, 1.4 Hz, 1H), 7.57 (d, J = 2.2 Hz, 1H), 7.43-7.37 (m, 2H), 7.18 (ddd, J =
8.5, 7.2, 1.2 Hz, 1H), 3.71 (s, 3H). 13C-NMR (125MHz, CDCl3)  167.9, 163.0, 146.7,
141.2, 136.4, 136.2, 135.8, 134.5, 133.7, 132.0, 130.8, 129.4, 126.4, 126.0, 123.9, 122.2,
120.5, 118.8, 41.0.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2bromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.68 (dd, J = 8.5, 1.0
Hz, 1H), 8.17-8.11 (m, 2H), 7.81 (d, J = 2.2 Hz, 1H), 7.71-7.66 (m, 1H), 7.63-7.57 (m,
2H), 7.41-7.36 (m, 2H), 7.16 (ddd, J = 8.5, 7.2, 1.2 Hz, 1H), 3.79 (s, 2H). 13C-NMR
(125MHz, CDCl3)  167.8, 162.7, 146.6, 136.6, 136.1, 135.9, 135.1, 134.5, 134.1, 133.8,
132.7, 130.7, 129.5, 127.6, 126.0, 123.9, 123.1, 122.4, 120.6, 118.8, 40.8.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3bromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.35 (s, 1H), 8.68 (dd, J = 8.5, 1.0
Hz, 1H), 8.22 (t, J = 1.0 Hz, 1H), 8.15 (dd, J = 8.4, 1.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H),
7.79 (d, J = 2.2 Hz, 1H), 7.75-7.71 (m, 1H), 7.64-7.61 (m, 1H), 7.57 (d, J = 2.1 Hz, 1H),
7.33 (t, J = 8.7 Hz, 1H), 7.18 (t, J = 8.6 Hz, 1H), 3.71 (s, 2H). 13C-NMR (125MHz,
CDCl3)  167.8, 162.5, 146.6, 137.5, 136.3, 135.8, 134.5, 133.8, 133.5, 130.8, 130.5,
129.9, 129.3, 126.0, 124.0, 123.0, 122.2, 120.6, 118.7, 41.0.
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4bromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.34 (s, 1H), 8.68 (dd, J = 8.5, 0.9
Hz, 1H), 8.16 (dd, J = 8.4, 1.0 Hz, 1H), 7.98 (d, J = 8.5 Hz), 7.79 (d, J = 2.3 Hz, 1H),
7.65-7.54 (m, 3H), 7.18 (t, J = 8.4 Hz, 1H), 3.71 (s, 2H). 13C-NMR (125MHz, CDCl3) 


167.9, 163.1, 146.7, 136.3, 135.8, 134.5, 133.7, 132.4, 132.1, 130.8, 130.0, 126.8, 126.0,
123.9, 122.2, 120.6, 118.8, 41.0.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2fluorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.67 (dd, J = 8.4, 0.9
Hz, 1H), 8.15 (dd, J = 8.5, 1.0 Hz, 1H), 8.06 (dt, J = 8.4, 0.9 Hz, 1H), 7.79 (d, J = 2.2 Hz,
1H), 7.64-7.55 (m, 2H), 7.24-7.11 (m,2H), 3.75 (s, 2H). 13C-NMR (125MHz, CDCl3)
167.8, 163.7, 161.6, 161.2, 161.1, 136.3, 136.2, 136.2, 135.8, 134.5, 133.7, 133.0, 130.7,
125.9, 124.5, 124.5, 123.9, 122.4, 120.5, 118.8, 117.6, 117.4, 116.7, 116.6, 40.8.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4fluorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.67 (d, J = 8.3 Hz,
1H), 8.20-8.11 (m, 2H), 7.79 (d, J = 1.9 Hz, 1H), 7.62 (t, J = 8.4 Hz, 1H), 7.57 (d, J = 1.8
Hz, 1H), 7.18 (t, J = 8.4 Hz, 1H), 7.14-7.07 (m, 2H), 3.71 (s, 2H). 13C-NMR (125MHz,
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CDCl3) 167.9, 167.8, 165.7, 162.8, 146.7, 136.5, 136.2, 135.7, 134.5, 133.7, 133.5,
133.4, 130.8, 126.0, 124.2, 123.9, 122.2, 120.5, 118.8, 116.4, 116.2, 40.9.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2methylbenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.68 (d, J = 8.4 Hz,
1H), 8.16 (d, J = 8.4 Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz, 1H), 7.80 (d, J = 2.0 Hz, 1H),
7.60 (t, J = 8.2 Hz, 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.44 (t, J = 8.2 Hz, 1H), 7.27-7.13 (m,
2H), 3.73 (s, 2H), 2.53 (s, 3H). 13C-NMR (125MHz, CDCl3) 168.0, 163.9, 147.0, 142.4,
136.5, 136.1, 135.7, 134.5, 133.7, 133.7, 132.3, 131.8, 130.9, 126.8, 126.2, 125.9, 123.8,
122.2, 120.2, 119.1, 41.0, 22.1.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3methylbenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.70 (dd, J = 8.4, 0.8
Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz), 7.94-7.89 (m, 2H), 7.78 (d, J = 2.1, Hz, 1H), 7.61 (t, J
= 8.2 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.43-7.37 (m, 1H), 7.30 (t, J = 8.4 Hz, 1H), 7.16
(t, J = 8.4 Hz, 1H), 3.71 (s, 2H), 2.33 (s, 3H). 13C-NMR (125MHz, CDCl3)  167.9,
163.9, 146.9, 138.9, 136.4, 136.2, 135.7, 135.4, 134.6, 133.7, 131.1, 130.9, 128.8, 127.9,
127.8, 125.9, 123.8, 122.2, 120.3, 118.9, 40.9, 21.4.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4methylbenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2-
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nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.69 (dd, J = 8.4, 0.9
Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz, 1H), 8.00 (d, J = 8.5 Hz, 2H), 7.78 (d, J = 2.1 Hz, 1H),
7.61 (t, J = 8.3 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H), 7.17 (t, J = 8.4
Hz, 1H), 3.71 (s, 2H), 2.40 (s, 3H). 13C-NMR (125MHz, CDCl3)  168.0, 163.8, 146.9,
145.6, 136.4, 136.2, 135.7, 134.6, 133.6, 131.0, 130.8, 129.6, 125.9, 125.1, 123.8, 122.3,
120.2, 118.9, 40.9, 22.1.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6dichlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the
desired product (XX% yield). 1H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.70 (d, J =
8.4 Hz, 1H), 8.16 (dd, J = 8.4, 1.0 Hz, 1H), 7.83 (d, J = 2.1 Hz, 1H), 7.64-7.57 (m, 2H),
7.41-7.31 (m, 2H), 7.16 (t, J = 8.4 Hz, 1H), 3.98 (s, 2H). 13C-NMR (125MHz, CDCl3) 


167.9, 161.9, 146.1, 136.6, 136.3, 136.2, 134.5, 134.1, 133.0, 132.2, 131.2, 130.5, 128.9,
126.0, 123.9, 122.3, 121.1, 118.6, 40.5.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6dibromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the
desired product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.32 (s, 1H), 8.72 (dd, J =
8.6, 1.3 Hz, 1H), 8.17 (dd, J = 8.5, 1.6 Hz, 1H), 7.85 (d, J = 2.3 Hz, 1H), 7.65 – 7.59 (m,
4H), 7.24 – 7.13 (m, 2H), 4.06 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.97, 145.95,
136.66, 136.20, 136.04, 135.00, 134.45, 133.99, 132.64, 132.56, 130.68, 125.88, 123.79,
122.36, 120.91, 118.45, 40.70. MISSING A C=O & SOME Ar
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2,4-dibromo-6-(2-((4,5-difluoro-2-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.41 (s, 1H), 8.74 (dd, J = 12.6,
7.5 Hz, 1H), 8.14 (dd, J = 7.9, 0.9 Hz, 1H), 8.07 (dd, J = 10.1, 7.9 Hz, 1H), 7.85 (d, J =
2.3, 0.7 Hz, 1H), 7.59 (d, 1H), 7.55 – 7.49 (m, 2H), 7.41 – 7.35 (m, 1H), 3.81 (s, 2H). 13C
NMR (101 MHz, CDCl3) δ 167.90, 162.12, 146.58, 136.02, 135.00, 134.18, 133.71,
132.55, 131.71, 130.14, 127.47, 127.05, 120.64, 118.93, 115.14, 114.93, 111.01, 110.76,
40.75.
2,4-dibromo-6-(2-oxo-2-(pyridin-2-ylamino)ethyl)phenyl 2-chlorobenzoate.
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.27 – 8.19 (m, 2H), 8.19 – 8.10 (m,
2H), 7.77 (d, J = 2.3 Hz, 1H), 7.70 – 7.64 (m, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.53 – 7.48
(m, 2H), 7.40 – 7.32 (m, 1H), 7.05 – 6.99 (m, 1H), 3.73 (s, 2H). 13C NMR (101 MHz,
CDCl3) δ 167.23, 162.64, 151.12, 147.96, 146.34, 138.49, 135.47, 135.01, 134.05,
133.44, 132.56, 131.66, 131.15, 127.73, 127.03, 120.48, 120.20, 118.56, 114.21, 39.73.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-nitrobenzoate.
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.35 (s, 1H), 8.68 (dd, J = 8.6, 1.3
Hz, 1H), 8.13 (dd, J = 8.5, 1.2 Hz, 1H), 8.10 (dd, J = 7.4, 1.6 Hz, 1H), 8.01 (dd, J = 7.8,
1.4 Hz, 1H), 7.79 (d, 1H), 7.77 – 7.69 (m, 2H), 7.63 (d, 1H), 7.62 – 7.56 (m, 1H), 7.20 –
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7.12 (m, 1H), 3.96 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.90, 162.39, 147.98,
145.87, 136.78, 135.86, 135.52, 134.37, 134.16, 133.47, 132.80, 131.18, 130.53, 126.30,
125.74, 124.55, 123.71, 122.51, 120.82, 118.26, 39.85.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl benzoate.
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.34 (s, 1H), 8.70 (dd, J = 8.5, 1.3
Hz, 1H), 8.18 – 8.12 (m, 3H), 7.81 (d, J = 2.2 Hz, 1H), 7.67 – 7.57 (m, 3H), 7.49 – 7.41
(m, 2H), 7.22 – 7.15 (m, 1H), 3.74 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.85,
163.71, 136.07, 135.65, 134.50, 134.45, 133.57, 130.85, 130.64, 128.87, 127.94, 125.86,
123.76, 122.23, 120.28, 40.83.

POSSIBLY MISSING SOME Ar

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2methoxybenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the
desired product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.29 (s, 1H), 8.70 (dd, J =
8.5, 1.3 Hz, 1H), 8.15 (dd, J = 8.4, 1.6 Hz, 1H), 8.02 (dd, J = 7.8, 1.8 Hz, 1H), 7.80 (d, J
= 2.3 Hz, 1H), 7.66 – 7.47 (m, 3H), 7.21 – 7.11 (m, 1H), 7.03 – 6.91 (m, 2H), 3.86 (s,
3H), 3.80 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 168.09, 162.72, 160.18, 146.93,
136.61, 135.95, 135.60, 135.16, 134.51, 133.54, 132.69, 130.81, 125.82, 123.71, 122.36,
120.40, 120.06, 119.02, 117.52, 112.24, 56.10, 40.65.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-iodobenzoate.
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2-
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nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.33 (s, 1H), 8.70 (dt, J = 8.5, 1.2
Hz, 1H), 8.23 – 8.13 (m, 2H), 8.05 (dt, J = 7.9, 1.2 Hz, 1H), 7.82 (dd, J = 2.4, 1.1 Hz,
1H), 7.65 – 7.57 (m, 2H), 7.47 – 7.39 (m, 1H), 7.26 – 7.13 (m, 2H), 3.80 (d, J = 1.0 Hz,
2H). 13C NMR (101 MHz, CDCl3) δ 167.72, 162.75, 142.23, 141.98, 136.02, 135.78,
135.03, 134.46, 134.11, 133.74, 132.34, 132.11, 130.68, 129.74, 128.30, 125.88, 123.80,
122.38, 120.54, 118.79, 40.81.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,5-difluoro-2nitrobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.34 (s, 1H), 8.67 (dd, J = 8.6, 1.3
Hz, 1H), 8.17 (dd, J = 8.5, 1.6 Hz, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.75 – 7.71 (m, 1H),
7.67 – 7.59 (m, 2H), 7.32 – 7.26 (m, 1H), 7.23 – 7.17 (m, 1H), 3.78 (s, 2H). 13C NMR
(101 MHz, CDCl3) δ 167.34, 164.11, 163.99, 158.86, 153.63, 145.64, 136.72, 136.08,
135.78, 134.30, 134.10, 133.52, 130.58, 125.85, 123.94, 122.42, 121.33, 118.13, 114.64,
110.54, 40.37.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-3fluoro-5-nitrobenzoate. Prepared according to the procedure provided for 2,4-dibromo6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of
the desired product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.39 (s, 1H), 8.80 (dd,
J = 2.6, 1.5 Hz, 1H), 8.70 (dd, J = 8.5, 1.3 Hz, 1H), 8.21 – 8.15 (m, 2H), 7.86 (d, J = 2.3
Hz, 1H), 7.67 – 7.60 (m, 2H), 7.23 – 7.16 (m, 1H), 3.80 (s, 2H). 13C NMR (101 MHz,
CDCl3) δ 167.40, 161.16, 160.05, 158.65, 147.33, 146.06, 136.24, 136.01, 134.32,

133

134.00, 132.53, 130.44, 125.94, 124.02, 122.51, 122.19, 121.25, 118.48, 115.32, 115.04,
41.16.
(S)-2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl
2-chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the
desired product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.21 (dd, J = 7.9, 1.2 Hz,
1H), 7.77 (dd, J = 2.3, 1.2 Hz, 1H), 7.59 – 7.53 (m, 3H), 7.47 – 7.40 (m, 1H), 6.18 (s,
1H), 4.55 – 4.35 (m, 2H), 4.29 – 4.14 (m, 1H), 3.61 (s, 2H), 2.76 – 2.61 (m, 1H), 2.16 –
1.99 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 174.76, 169.16, 135.45, 135.02, 134.32,
133.47, 132.70, 131.78, 131.23, 127.48, 127.21, 120.57, 118.45, 66.07, 49.53, 38.19,
29.81.
2,4-dibromo-6-(2-((3-nitropyridin-4-yl)amino)-2-oxoethyl)phenyl 2chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.50 (s, 1H), 9.33 (s, 1H), 8.67 (s,
2H), 8.13 (dd, 1H), 7.86 (d, J = 2.2 Hz, 1H), 7.59 (d, J = 2.3 Hz, 1H), 7.56 – 7.47 (m,
2H), 7.41 – 7.34 (m, 1H), 3.84 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 168.31, 162.10,
156.31, 155.69, 136.16, 134.22, 133.69, 132.54, 131.72, 129.85, 129.27, 128.07, 127.41,
127.06, 120.70, 118.99, 114.62, 40.90.
2,4-dibromo-6-(2-oxo-2-(pyrimidin-4-ylamino)ethyl)phenyl 2-chlorobenzoate.
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
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product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.83 (s, 1H), 8.61 (s, 1H), 8.34 (s,
1H), 8.21 – 8.14 (m, 1H), 8.10 (dd, J = 5.8, 1.2 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.57 (d,
J = 2.4 Hz, 1H), 7.55 – 7.52 (m, 2H), 7.42 – 7.36 (m, 1H), 3.76 (s, 2H). 13C NMR (101
MHz, CDCl3) δ 168.19, 162.98, 158.59, 158.49, 156.87, 146.25, 135.79, 135.03, 134.27,
133.32, 132.57, 131.73, 130.43, 127.54, 127.12, 120.67, 118.71, 110.42, 39.79.
2-(3,5-dibromo-2-((2,6-dichlorobenzyl)oxy)phenyl)-N-(2nitrophenyl)acetamide. Prepared according to the procedure provided for 2,4-dibromo6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of
the desired product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.13 (s, 1H), 8.62 (dd,
J = 8.6, 1.3 Hz, 1H), 8.13 (dd, J = 8.5, 1.6 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.59 – 7.51
(m, 1H), 7.34 (d, J = 2.4 Hz, 1H), 7.25 – 7.21 (m, 2H), 7.17 – 7.07 (m, 2H), 5.45 (s, 2H),
3.54 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 168.67, 153.71, 137.34, 136.56, 136.06,
135.91, 134.66, 133.49, 132.13, 131.17, 131.00, 128.81, 125.79, 123.52, 122.35, 118.51,
117.84, 70.16, 39.81.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,5dichloroisonicotinate. Prepared according to the procedure provided for 2,4-dibromo-6(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the
desired product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.39 (s, 1H), 8.68 (dd, J =
8.5, 1.3 Hz, 1H), 8.54 (s, 1H), 8.19 (dd, J = 8.5, 1.6 Hz, 1H), 7.95 (d, J = 0.7 Hz, 1H),
7.85 (d, J = 2.2 Hz, 1H), 7.68 – 7.59 (m, 2H), 7.24 – 7.16 (m, 1H), 3.79 (s, 2H). 13C
NMR (101 MHz, CDCl3) δ 167.37, 165.04, 151.43, 150.39, 145.91, 143.70, 142.51,
138.80, 136.25, 135.99, 134.28, 133.96, 130.32, 125.99, 125.67, 124.04, 122.13, 121.27,
118.40, 40.97.
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2,4-dibromo-6-(2-((2,3-difluorophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, Acetone-d6) δ 9.17 (s, 1H), 8.11 (dd, J = 7.9,
1.6 Hz, 1H), 7.80 (t, J = 7.4 Hz, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.65 (d, J = 2.3 Hz, 1H),
7.57 – 7.46 (m, 2H), 7.38 – 7.31 (m, 1H), 7.03 – 6.94 (m, 1H), 6.94 – 6.85 (m, 1H), 3.86
(s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.08, 162.99, 146.01, 135.52, 135.05, 134.31,
133.18, 133.15, 132.57, 131.73, 131.12, 127.83, 127.46, 127.13, 124.21, 120.63, 118.48,
117.08, 112.62, 112.45, 39.66.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,6dichloropicolinate. Prepared according to the procedure provided for 2,4-dibromo-6-(2((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the
desired product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.38 (s, 1H), 8.67 (dd, J =
8.5, 1.8 Hz, 1H), 8.17 (dd, 1H), 7.83 – 7.78 (m, 2H), 7.65 – 7.58 (m, 2H), 7.46 (dd, J =
8.5, 1.4 Hz, 1H), 7.22 – 7.14 (m, 1H), 3.85 (s, 2H). 13C NMR (101 MHz, CDCl3) δ
167.62, 159.73, 149.38, 146.28, 144.97, 141.72, 140.81, 139.18, 136.94, 135.92, 135.78,
134.41, 133.85, 130.49, 128.73, 125.81, 123.86, 122.75, 120.80, 40.42.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 5-fluoro-2nitrobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.36 (s, 1H), 8.68 (dd, J = 8.5, 1.3
Hz, 1H), 8.18 – 8.10 (m, 2H), 7.81 (d, J = 2.3 Hz, 1H), 7.75 (dd, J = 7.7, 2.7 Hz, 1H),
7.64 (d, J = 2.3 Hz, 1H), 7.64 – 7.58 (m, 1H), 7.43 – 7.34 (m, 1H), 7.20 – 7.13 (m, 1H),
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3.98 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.86, 166.07, 161.41, 145.64, 135.93,
135.62, 134.41, 134.33, 131.20, 127.63, 127.53, 125.81, 123.78, 122.53, 121.10, 119.49,
119.25, 118.20, 117.96, 117.70, 39.87.
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-4fluorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 10.34 (s, 1H), 8.69 (dd, J = 8.5, 1.3
Hz, 1H), 8.17 (dd, J = 8.5, 1.5 Hz, 1H), 7.99 – 7.92 (m, 1H), 7.83 (d, J = 2.3 Hz, 1H),
7.63 – 7.58 (m, 2H), 7.45 – 7.30 (m, 2H), 7.22 – 7.15 (m, 1H), 3.81 (s, 2H). 13C NMR
(101 MHz, CDCl3) δ 167.64, 161.84, 146.40, 138.59, 136.55, 136.08, 135.85, 134.37,
133.80, 131.53, 130.52, 128.88, 128.80, 127.94, 125.89, 123.88, 122.26, 120.84, 120.60,
118.68, 40.80.
2,4-dibromo-6-(2-((3-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.41 (t, J = 2.2 Hz, 1H), 8.26 (d, J =
7.4 Hz, 1H), 8.02 (s, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.81 (d, J =
2.3 Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.60 – 7.53 (m, 2H), 7.51 – 7.38 (m, 2H), 3.74 (s,
2H).
2,4-dibromo-6-(2-((4-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
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product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.26 (dd, J = 8.1, 1.5 Hz, 1H), 8.20
– 8.15 (m, 2H), 8.14 (s, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.74 – 7.67 (m, 2H), 7.64 – 7.54
(m, 3H), 7.50 – 7.42 (m, 1H), 3.74 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.37,
164.71, 145.84, 143.77, 143.73, 135.85, 135.35, 134.81, 133.17, 132.76, 131.93, 130.93,
127.32, 127.00, 125.08, 121.14, 119.31, 118.63, 39.64.
2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl 4(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoate. Prepared according to the procedure
provided for 2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate, affording XX mg of the desired product (XX% yield). 1H NMR (400
MHz, Chloroform-d) δ 7.67 (d, J = 2.3 Hz, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.14 (s, 1H),
6.77 (s, 2H), 4.59 – 4.48 (m, 1H), 4.44 (t, 1H), 4.32 – 4.21 (m, 1H), 3.77 – 3.64 (m, 2H),
2.89 – 2.79 (m, 1H), 2.84 – 2.67 (m, 2H), 2.20 – 2.01 (m, 2H). 13C NMR (101 MHz,
Chloroform-d) δ 175.30, 171.77, 170.42, 169.82, 134.90, 134.56, 134.06, 131.72, 120.02,
66.36, 49.73, 37.50, 36.68, 31.16, 30.62, 30.51, 23.69.
2,4-dibromo-6-((2-nitrobenzamido)methyl)phenyl 2-chlorobenzoate. To 2(benzyloxy)-3,5-dibromophenyl)methanamine (64.0 mg, 0.173 mmol) in CH2Cl2 (3.45
mL, 0.05 M) under N2 was added 2-nitrobenzoyl chloride (35.5 mg, 0.191 mmol),
followed by Et3N (58 µL, 0.415 mmol) and then DMAP (2.1 mg, 0.0173 mmol). The
mixture was allowed to stir overnight at room temperature and then was diluted with
CH2Cl2 (50 mL) and washed with HCl (25 mL, 1 M), sat. NaHCO3 (25 mL) and then
brine (25 mL). After drying over Na2SO4, the material was purified via silica-gel flash
chromatography, affording XX mg of the desired product (XX% yield). 1H and 13C-NMR
match previously published spectra.
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2,4-dibromo-6-(picolinamidomethyl)phenyl 2-chlorobenzoate. Prepared
according to the procedure provided for 2,4-dibromo-6-((2
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.54 (dd, J = 4.7, 1.4 Hz, 1H), 8.45
(s, 1H), 8.21 (dd, J = 7.8, 1.1 Hz, 1H), 8.15 (dd, J = 7.8, 1.1 Hz, 1H), 7.84 (td, J = 7.8,
1.8 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.54 (d, 2H), 7.46 – 7.39
(m, 2H), 4.66 (d, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 164.56, 162.48, 149.41,
148.35, 145.84, 137.52, 135.04, 134.94, 133.99, 132.61, 131.78, 131.65, 127.89, 127.00,
126.59, 122.51, 120.33, 118.12, 38.74.
2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2nitrobenzenesulfonate. Prepared according to the procedure provided for 2,4-dibromo6-((2 nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.16 (dd, 1H), 8.08 – 8.05 (m, 1H),
7.94 – 7.87 (m, 3H), 7.84 – 7.78 (m, 1H), 7.76 – 7.72 (m, 2H), 7.71 (d, J = 2.3 Hz, 1H),
7.61 (d, J = 2.3 Hz, 1H), 6.21 (s, 1H), 4.48 (s, 2H). 13C NMR (101 MHz, CDCl3) δ
147.80, 144.20, 136.18, 136.13, 135.12, 133.99, 133.51, 133.35, 133.14, 132.85, 131.98,
131.00, 129.61, 125.78, 125.51, 121.88, 118.12, 43.26.
2,4-dibromo-6-(picolinamidomethyl)phenyl 4-(2,5-dioxo-2,5-dihydro-1Hpyrrol-1-yl)butanoate. Prepared according to the procedure provided for 2,4-dibromo-6((2 nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.53 (dd, J = 4.8, 1.3 Hz, 1H), 8.41
(s, 1H), 8.19 (dd, J = 7.8, 1.2 Hz, 1H), 7.86 (td, J = 7.7, 1.7 Hz, 1H), 7.66 (d, J = 2.3 Hz,
1H), 7.53 (d, J = 2.3 Hz, 1H), 7.47 – 7.39 (m, 1H), 6.72 (s, 2H), 4.59 (d, J = 6.4 Hz, 2H),
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3.68 (t, J = 6.7 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.10 – 1.98 (m, 2H). 13C NMR (101
MHz, CDCl3) δ 170.94, 170.02, 164.39, 149.49, 148.32, 146.02, 137.56, 134.94, 134.82,
134.31, 132.05, 126.56, 122.53, 119.96, 118.15, 38.75, 36.98, 31.20, 23.79.
2,4-dibromo-6-(picolinamidomethyl)phenyl 2-nitrobenzoate. Prepared
according to the procedure provided for 2,4-dibromo-6-((2
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.58 (t, J = 6.5 Hz, 1H), 8.55 – 8.50
(m, 1H), 8.19 – 8.12 (m, 2H), 8.02 (dd, J = 7.7, 1.5 Hz, 1H), 7.86 – 7.71 (m, 3H), 7.70 (d,
J = 2.3 Hz, 1H), 7.64 (d, J = 2.3 Hz, 1H), 7.44 – 7.39 (m, 1H), 4.75 (d, J = 6.5 Hz, 2H).
13

C NMR (101 MHz, CDCl3) δ 164.74, 162.45, 149.46, 148.36, 148.18, 145.10, 137.43,

135.61, 134.89, 133.39, 132.90, 132.19, 130.74, 126.50, 126.17, 124.46, 122.42, 120.79,
117.70, 38.39.
2,4-dibromo-6-((2-nitrobenzamido)methyl)phenyl 2-nitrobenzoate. Prepared
according to the procedure provided for 2,4-dibromo-6-((2
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.17 (dd, J = 7.5, 1.6 Hz, 1H), 8.00
(td, J = 7.8, 1.3 Hz, 2H), 7.84 (d, J = 2.4 Hz, 1H), 7.83 – 7.75 (m, 2H), 7.75 (d, J = 2.3
Hz, 1H), 7.64 (td, J = 7.5, 1.3 Hz, 1H), 7.59 – 7.47 (m, 2H), 6.63 (t, J = 6.1 Hz, 1H), 4.68
(s, 2H). 13C NMR (101 MHz, CDCl3) δ 166.66, 162.90, 148.28, 146.81, 145.30, 135.43,
134.56, 133.79, 133.72, 133.62, 133.15, 132.31, 130.88, 130.82, 128.80, 126.00, 124.70,
124.53, 121.00, 117.52, 39.06.
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2,4-dibromo-6-((2,3-difluorobenzamido)methyl)phenyl 2-chlorobenzoate.
Prepared according to the procedure provided for 2,4-dibromo-6-((2
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.21 (dd, 1H), 7.81 – 7.73 (m, 2H),
7.62 (d, J = 2.3 Hz, 1H), 7.57 – 7.53 (m, 2H), 7.46 – 7.40 (m, 1H), 7.36 – 7.27 (m, 1H),
7.21 – 7.14 (m, 1H), 7.04 (t, J = 11.4 Hz, 1H), 4.66 (s, 2H). 13C NMR (101 MHz, CDCl3)
δ 162.73, 162.47, 145.94, 135.36, 134.98, 134.44, 134.12, 132.55, 132.25, 131.69,
127.75, 127.09, 126.60, 126.57, 124.78, 124.72, 120.83, 120.65, 120.43, 118.16, 39.40.
2,4-dibromo-6-((2-chloro-N-((2nitrophenyl)sulfonyl)benzamido)methyl)phenyl 2-chlorobenzoate. Prepared
according to the procedure provided for 2,4-dibromo-6-((2
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.33 (dd, J = 7.9, 1.5 Hz, 1H), 8.12
(dd, J = 7.6, 1.1 Hz, 1H), 7.87 (dd, J = 7.9, 1.5 Hz, 1H), 7.80 (td, J = 7.6, 1.5 Hz, 1H),
7.76 – 7.69 (m, 2H), 7.57 – 7.51 (m, 3H), 7.46 – 7.39 (m, 1H), 7.37 – 7.30 (m, 1H), 7.24
(dd, J = 8.2, 1.1 Hz, 1H), 7.18 (td, J = 7.5, 1.2 Hz, 1H), 7.15 – 7.10 (m, 1H), 5.08 (s, 2H).
13

C NMR (101 MHz, CDCl3) δ 167.61, 165.85, 161.99, 148.04, 145.12, 135.52, 135.35,

135.32, 134.91, 133.83, 133.26, 133.21, 132.52, 132.35, 132.01, 131.90, 131.45, 131.07,
130.07, 127.98, 126.95, 126.86, 126.86, 125.08, 120.26, 118.13, 77.48, 77.16, 76.84,
47.29.
2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-((2
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
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product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.22 (dd, 1H), 8.00 – 7.87 (m, 2H),
7.86 – 7.80 (m, 2H), 7.66 (d, J = 2.4, 1.0 Hz, 1H), 7.64 (dd, 1H), 7.41 – 7.27 (m, 2H),
7.06 (t, J = 6.4 Hz, 1H), 4.78 (d, J = 6.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 166.97,
148.57, 144.57, 136.76, 136.07, 135.78, 134.50, 133.77, 132.81, 131.94, 131.64, 131.05,
130.45, 130.14, 129.87, 127.19, 125.50, 121.89, 117.98, 39.45.
2,4-dibromo-6-(nicotinamidomethyl)phenyl 2-chlorobenzoate. Prepared
according to the procedure provided for 2,4-dibromo-6-((2
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired
product (XX% yield). 1H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.71 (s, 1H), 8.21 (dd,
1H), 8.07 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.58 –
7.50 (m, 2H), 7.47 – 7.39 (m, 1H), 7.39 – 7.33 (m, 1H), 6.80 (t, 1H), 4.63 (s, 2H). 13C
NMR (101 MHz, CDCl3) δ 165.40, 163.37, 152.55, 148.24, 146.10, 135.58, 135.21,
135.00, 134.32, 132.79, 132.64, 131.74, 127.52, 127.17, 123.63, 120.52, 118.19, 39.50.
2,4-dibromo-6-((pyrimidine-4-carboxamido)methyl)phenyl 2-chlorobenzoate.
1

H NMR (400 MHz, Chloroform-d) δ 9.22 (d, J = 1.4 Hz, 1H), 8.96 (d, J = 5.0 Hz, 1H),

8.38 (t, 1H), 8.20 (d, 1H), 8.06 (d, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.61 – 7.52 (m, 2H),
7.48 – 7.38 (m, 1H), 4.66 (d, J = 6.3 Hz, 2H). 13C NMR (101 MHz, Chloroform-d) δ
162.91, 162.64, 159.41, 157.96, 155.96, 146.08, 135.49, 134.27, 134.21, 132.72, 132.17,
131.77, 127.84, 127.15, 126.84, 120.46, 118.87, 118.39, 39.10.
2,4-dibromo-6-(((2-cyanophenyl)sulfonamido)methyl)phenyl 2chlorobenzoate. 1H NMR (400 MHz, Chloroform-d) δ 8.23 – 8.14 (m, 1H), 8.01 – 7.94
(m, 1H), 7.89 – 7.82 (m, 3H), 7.69 – 7.60 (m, 2H), 7.39 – 7.32 (m, 2H), 7.12 (t, J = 6.5
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Hz, 1H), 4.86 (d, J = 6.4 Hz, 2H), 4.53 (s, 1H). 13C NMR (101 MHz, Chloroform-d) δ
167.17, 144.43, 138.58, 137.11, 135.84, 135.76, 134.98, 134.71, 134.03, 133.45, 131.72,
131.20, 130.68, 130.54, 130.22, 127.29, 122.06, 117.78, 115.37, 112.35, 39.61.

143

(2-(benzyloxy)-3,5-dibromophenyl)methanamine

144

N-(2-(benzyloxy)-3,5-dibromobenzyl)-2-nitrobenzamide

145

N-(3,5-dibromo-2-hydroxybenzyl)-2-nitrobenzamide

146

2-(2-methoxyphenyl)-N-(2-nitrophenyl)acetamide

147

2-(2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide

148

2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide

149

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate

150

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-chlorobenzoate

151

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-chlorobenzoate

152

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromobenzoate

153

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-bromobenzoate

154

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-bromobenzoate

155

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-fluorobenzoate

156

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-fluorobenzoate

157

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-methylbenzoate

158

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-methylbenzoate

159

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-methylbenzoate

160

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6-dichlorobenzoate

161

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6-dibromobenzoate

162

2,4-dibromo-6-(2-((4,5-difluoro-2-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate
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2,4-dibromo-6-(2-oxo-2-(pyridin-2-ylamino)ethyl)phenyl 2-chlorobenzoate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-nitrobenzoate

165

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl benzoate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-methoxybenzoate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-iodobenzoate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,5-difluoro-2nitrobenzoate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-3-fluoro-5nitrobenzoate
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(S)-2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl 2chlorobenzoate
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2,4-dibromo-6-(2-((3-nitropyridin-4-yl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate
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2,4-dibromo-6-(2-oxo-2-(pyrimidin-4-ylamino)ethyl)phenyl 2-chlorobenzoate
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2-(3,5-dibromo-2-((2,6-dichlorobenzyl)oxy)phenyl)-N-(2-nitrophenyl)acetamide
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,5dichloroisonicotinate
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2,4-dibromo-6-(2-((2,3-difluorophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,6-dichloropicolinate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 5-fluoro-2nitrobenzoate
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-4fluorobenzoate.
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2,4-dibromo-6-(2-((3-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate
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2,4-dibromo-6-(2-((4-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate
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2,4-dibromo-6-(picolinamidomethyl)phenyl 2-chlorobenzoate
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2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2-nitrobenzenesulfonate
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2,4-dibromo-6-(picolinamidomethyl)phenyl 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1yl)butanoate.
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2,4-dibromo-6-(picolinamidomethyl)phenyl 2-nitrobenzoate
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2,4-dibromo-6-((2-nitrobenzamido)methyl)phenyl 2-nitrobenzoate
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2,4-dibromo-6-((2,3-difluorobenzamido)methyl)phenyl 2-chlorobenzoate
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2,4-dibromo-6-((2-chloro-N-((2-nitrophenyl)sulfonyl)benzamido)methyl)phenyl 2chlorobenzoate
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2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2-chlorobenzoate
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Chapter 5
Lipoxin A4 augments host defense in sepsis and reduces P. aeruginosa virulence
through quorum sensing inhibition
Introduction
In bacterial infections, signaling through pathogen associated molecular pattern
(PAMP) recognition receptors activate the innate immune system1. The subsequent
increased release of inflammatory mediators such as cytokines, arachidonic acid
metabolites and free radicals is critical for bacterial clearance, but if sustained, can cause
tissue injury, multiple organ failure and death. Alternatively, a sustained inflammatory
response may lead to a delayed dysregulation of inflammatory response, characterized by
an inability of populations of lymphocytes and/or monocytes/macrophages to secrete
inflammatory cytokines when stimulated2-7. In this immunocompromised condition, the
host is susceptible to opportunistic infections or cannot clear preexisting infections. It is
important to resolve infection as continued bacterial load will cause persistent proinflammatory or dysregulated inflammatory response without returning to homeostasis.
Therefore, an appropriate infection resolution can be defined as one which clears
the infectious agent without causing tissue injury and/or an immunosuppressed state. The
role of neutrophils in severe infections is complex. Neutrophils are first activated to
combat the infectious agent. They migrate to the site of infection, release a host of proinflammatory mediators such as free radicals and leukotrienes, phagocytose bacteria
before dying by apoptosis. Sustained neutrophil activation however can cause tissue
injury and organ damage8-10. On the other hand, a paradoxical dysregulation in neutrophil
function can also occur in later phases of severe infections/sepsis11-14. Indeed, insufficient
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neutrophil phagocytic activity and impaired neutrophil migration is an indicator of poor
outcome in sepsis12,15,16.
Inflammation resolution is an active process which involves inhibition of
neutrophil activation, increased macrophage recruitment and macrophage phagocytosis of
apoptotic neutrophils17-19. Specialized pro-resolving mediators (SPMs) such as the
Lipoxins and Resolvins have been shown to resolve inflammation in sterile models of
inflammation20-23 while reducing inflammatory response and bacterial load in various
infectious models24-30. We have previously reported that Lipoxin A4 (LXA4) reduced
blood bacterial load, decreased systemic inflammatory response and increased survival in
the cecal ligation puncture (CLP) model of polymicrobial sepsis29,30. LXA4 increased
bacterial clearance at least partially through promotion of neutrophil phagocytic
function31. Fcg receptor I (FcgRI;CD64) is an important neutrophil receptor in
infection15,16,32 where it functions to increase uptake of bacteria33,35. As increased
expression has been reported to be a prognosticator of good outcome in sepsis15, we
investigated if LXA4 promoted neutrophil phagocytic activity through stimulation of
FcgRI mediated phagocytosis.
During infection, in addition to host signaling pathways regulating inflammatory
response there are also separate chemical regulatory pathways at work in the bacterial
pathogen that are critical for the establishment and propagation of the infection. This
bacterial population density-dependent process of chemical signaling is called quorum
sensing (QS). The process of QS involves the bacterial production, release and detection
of structurally specific small molecules and enables the bacterial pathogen to regulate its
virulence by switching on genes that increase biofilm formation, toxin release and/or
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antibiotic resistance36,43. As anti-inflammatory agents may cause immunosuppression
where the host is not able to clear pathogen and standard antibiotics do not affect
inflammatory response, the most efficient treatment modality for severe bacterial
infections would be to resolve inflammation and reduce bacterial virulence.
A large number of structurally distinct QS molecules in both gram-negative and
gram-positive bacteria have been identified including oligopeptides, acylhomoserine
lactones (AHLs), the furanosyl borate ester (AI-2), and a-amino/hydroxy ketones36,44.
The gram-negative bacteria pathogen, Pseudomonas aeruginosa utilizes at least three
separate chemical signals in its regulation of a diverse array of virulence factors such as
pyocyanin, elastase, HCN, rhamnolipids and biofilms. This network of QS regulation is
arranged hierarchically with the LasR quorum sensing receptor which recognizes the
AHL signaling molecule, N-3-oxododecanolyl homoserine lactone (3-oxo-C12 HSL) as
its native agonist representing the master QS circuit in this bacteria41. Binding of 3-oxoC12 HSL to the LasR QS receptor results in the activation/repression of numerous
downstream genes through the action of the ligand-bound LasR as a transcription factor
which upregulates the expression of virulence factors. Due to the central role of LasR in
the virulence of this bacteria, inhibition of QS signaling in P. aeruginosa represents a
novel target to reduce bacterial virulence45,46. As some synthetic inhibitors/activators of
LasR have similar chemical structure to LXA4, we reasoned that LXA4 may have quorum
sensing inhibitory activity.
In this study, we investigated if the SPM, LXA4, could modulate FcgRI mediated
phagocytosis of neutrophils in the CLP model of sepsis. Additionally, we examined if
LXA4 could interfere with bacteria signaling and reduce virulence. The goal of the study
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was to elucidate if LXA4 has the unique property of modulating both host defense to
increase bacterial clearance as well as reduce pathogen virulence. Such a compound
could contribute a therapeutic advantage as an antimicrobial.
Results
Blood bacterial load: There is clear evidence of bacterial infection in the blood
of CLP mice (Figure 1). LXA4 (7 mg/kg) given 1h after CLP surgery reduced bacterial
load significantly.
Neutrophil apoptosis and free radical production: Decreased neutrophil
apoptosis as a result of infection has been well established51-53. This increased life span of
neutrophils with attendant overproduction of inflammatory mediators is thought to
contribute to tissue injury associated with severe infections and sepsis8-10,51-53. In our
studies, blood leukocytes were isolated 24h after surgery from sham controls, CLP mice
given vehicle saline or CLP + LXA4 mice. The leukocytes were stained with

the

apoptosis marker Annexin V and Gr-1 as a marker for neutrophils. Neutrophil apoptosis
significantly decreased at 24h after CLP surgery compared to sham controls (Figure 2a).
LXA4 completely reversed the decreased neutrophil apoptosis in CLP mice. Neutrophil
ability to produce free radicals was evaluated by measuring the superoxide mediated
oxidation of non-fluorescent DHR 123 to the fluorescent rhodamine 123 after PMA
stimulation. CLP reduced neutrophil free radical generation ability and LXA4
administration did not further affect superoxide generation after CLP (Figure 2b).
Neutrophil phagocytic ability and CD64 expression: As neutrophil phagocytic
ability is essential for bacterial clearance, we evaluated the effect of LXA 4 on neutrophil
ability to engulf fluorescently labeled E.coli in sham control or septic mice. Blood
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leukocytes were isolated from sham controls, CLP or CLP + LXA4 treated mice, 24h
after surgery. Cells were incubated with pHrodo E.coli for 1h before being stained with
fluorescent Gr-1 antibody to label neutrophils. Blood neutrophils from CLP mice had
greater phagocytic ability compared to sham controls and LXA4 administration increased
phagocytic ability further (Figure 3a). As CD64 is a high affinity receptor which is
critically important in the initiation of neutrophil phagocytosis, its expression was
measured. We also measured the expression of FcgRIII and II using CD16/32 mouse
antibodies. CLP increased the percentage of CD64 expressing neutrophils compared to
sham controls and LXA4 increased this further. CD16/32 expression was not affected by
CLP or LXA4 (Figure 3b).
CD64 blocking antibody studies: To confirm that CD64 is important in the
LXA4 induced increase in neutrophil phagocytosis, we incubated leukocytes with CD64
blocking antibody or vehicle saline. The results show that CD64 antibody completely
abolished LXA4-induced increase in phagocytosis (Figure 4) suggesting that the LXA4
induced increase in neutrophil phagocytosis is mediated by CD64.
Ex vivo studies: To investigate if LXA4 increased neutrophil phagocytosis
directly, we isolated leukocytes from CLP or sham control mice 1h after surgery and
incubated these cells with LXA4 or vehicle saline for 3h before addition of fluorescent
E.coli to measure phagocytic ability. To confirm the specificity of LXA4, some cells were
incubated with WRW4 a specific blocker of the LXA4 formyl peptide receptor 2
(FPR2)(54). As expected, CLP mice had substantially greater percentage of neutrophils
which expressed CD64 compared to sham controls (Figure 5a). Interestingly, LXA4 did
not increase the percentage of neutrophils expressing CD64. This is in contrast to the in
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vivo actions of LXA4 which significantly increased the percentage of CD64 expressing
cells. These data suggest that LXA4 does not directly promote neutrophil CD64
expression. In CLP mice, LXA4 increased neutrophil phagocytosis and this increase was
completely abolished by the specific LXA4 receptor antagonist (Figure 5b). LXA4
however, had no effect on phagocytic ability of control neutrophils where there was
minimal CD64 expression (Figure 5c). Taken together with CD64 data, the results
support the postulate that LXA4 increases CD64-dependent neutrophil phagocytosis but
does not directly increase expression of CD64.
Inhibition of pyocyanin expression by LXA4: To evaluate if LXA4 directly
influences bacterial virulence we evaluated expression levels of the exotoxin, pyocyanin,
in the prominent bacterial pathogen P. aeruginosa (PA-14)55. While absorbance based
methods for the quantification of pyocyanin have been reported, we found this assay to
be complicated by low detection limit and requirement for multiple sample manipulation
steps. Accordingly, we utilized a UPLC-MS-MS based approach to determine the
concentration of pyocyanin in bacterial cultures. This method provides direct ion

counts

of the molecular ion for pyocyanin after UPLC separation from other culture constituents
and the identity of pyocyanin is further confirmed through analysis of the fragmentation
pattern of the isolated molecular ion. Further, no mathematical correction needs to be
applied as the concentration of pyocyanin is directly correlated to a calibration curve
generated using pure pyocyanin. In this analysis, we found that in the presence of 1-5 nM
of LXA4, pyocyanin concentration in bacterial culture was decreased (Figure 6).
Interestingly, we found that increasing the concentration of LXA4 further (8 nM)
abolished this effect. Taken together these results suggest a bell-shaped inhibitory curve
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for LXA4 on the expression of the bacterial virulence factor pyocyanin. This pattern of
LXA4 inhibition has been noted in other systems56,57.
Inhibition of LasR QS by LXA4: The regulation of virulence factor expression,
including pyocyanin expression, in P. aeruginosa occurs through a complex regulatory
network. The master QS receptor, LasR, plays a central role in this regulatory network
and we looked to evaluate if the observed inhibition of pyocyanin by LXA4 might be
occurring through inhibition of LasR. Upon analysis using a GFP-based reporter strain
for the activity of the transcription factor LasR, we found potent antagonism of LasR by
LXA4 at concentrations above 1.8 nM (Figure 7a). Generating a full dose-response curve
to evaluate the antagonist activity of LXA4 on LasR we observed partial antagonism,
achieving approximately 57% inhibition at the highest concentration tested (100 nM) as
compared to the known LasR antagonist, Br-HSL at 10 mM. While only partial
antagonism was observed, the potency of inhibition as defined by the IC50 of LXA4
(57nM) (Table 1, supplemental data), makes LXA4 the most potent antagonist of LasR
yet described43. We turned to evaluate the binding kinetics of the LasR inhibitory activity
of LXA4 using competition binding assays, locking the concentration of LXA4 while
titrating the native LasR agonist, 3-oxo-C12 HSL. In this assay we observed a shift in the
EC50 value for the LasR agonist 3-oxo-C12 HSL in the presence of increasing
concentrations of LXA4 (Figure 8; Table 2, supplemental data). Together, these results
are consistent with LXA4 acting as a highly potent reversible partial antagonist of the P.
aeruginosa master QS regulator, LasR. LXA4 is also a partial LasR agonist. The partial
agonist activity of LXA4 is anticipated from the previous assay demonstrating partial
antagonist activity for this compound. In this assay the native agonist was not fully
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titrated leading to the incomplete dose-response curve for this control compound,
however the different levels of maximal activation expected from LXA4 acting as a
partial agonist are clearly defined.
Discussion
Effective resolution of infection and/or inflammation is now believed to be an
active process18,19,58. As part of the early innate immune system, neutrophils are activated
to help clear the invading pathogen. Excessive neutrophil activation however, may lead to
tissue injury and damage while impaired neutrophil activity which can occur later in
sepsis, may result in reduced bacterial clearance11-14. Ideally therefore, neutrophil
activation and subsequent apoptosis are critical for inflammation resolution and to
achieve homeostasis in the host44,59,60.
SPMs have been reported to have significant pro-resolution effects in various
non-infectious, infectious and sepsis models20-22,25,26,28-30,45,61-64. The underlying
mechanism for these beneficial effects is believed to be due to the resolution effects on
different populations of cells including neutrophils and macrophages25-27,29,30,60,61,65-67.
With respect to infection, we and others have consistently shown that SPMs such as
LXA4 could simultaneously reduce bacterial load and inflammatory response28-30. The
timing of administration may be of importance because overly robust down regulation of
neutrophil function may produce unwanted bacterial spread54.
CD64 expression is important for neutrophil activation and phagocytic ability
(33,68). There is evidence that neutrophil CD64 expression can be used as a selective
biomarker for infection where highest levels of expression were found in patients with
infection compared to patients with autoimmune disorders which were
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themselves

significantly higher than normal patients or patients with inactive disease 69. In addition,
studies have now linked increased neutrophil CD64 expression with better outcome in
sepsis15. The possible reason for this is because neutrophil phagocytic action is increased
and may augment bacterial clearance. In our studies, in vivo administration of LXA4 to
CLP mice increased neutrophil phagocytic ability and CD64 expression without altering
CD16/32 expression. In addition, use of CD64 blocking antibody abolished the increase
in phagocytic ability in neutrophils isolated from LXA4-treated animals. These results
correlated with a significant decrease in blood bacterial load suggesting that augmented
CD64-dependent neutrophil phagocytic ability may be partially responsible for the
decreased bacterial load with LXA4 administration. The increase in phagocytic ability is
consistent with the action of a related SPM, Resolvin E1 which was also reported to
increase neutrophil phagocytic ability25.
To study the effects of LXA4 on neutrophils further, peripheral blood neutrophils
taken from CLP mice after 1h, were incubated with different concentrations of LXA4.
Under these conditions, LXA4 increased neutrophil phagocytic ability without affecting
expression of CD64. Importantly, LXA4 did not affect neutrophil phagocytic ability in
cells taken from control animals where CD64 expression was minimal. These results
suggest that LXA4 directly increased CD64-dependent neutrophil phagocytic ability
providing evidence that concentrations of LXA4 that produce a significant biological
effect in neutrophils only affected the phagocytic activity of already activated
neutrophils. These results are consistent with in vitro studies showing that

LXA4

inhibited stimulated neutrophil chemotactic responses65 but do not directly affect
quiescent neutrophil phagocytic activity66. Use of a specific LXA4 receptor (FPR-2)
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blocker completely abolished LXA4 effects on neutrophil phagocytic ability confirming
the receptor binding specificity of the LXA4 in these studies. These ex vivo results differ
from our in vivo data in that administration of LXA4 in vivo resulted in an increased
CD64 expression in neutrophils. The mechanism for this difference is unknown but may
indicate that LXA4 by itself is unable to increase CD64 expression in neutrophils or that
neutrophils from LXA4 treated septic mice are more responsive to CD64 inducing agents
such as IFN-g or G-CSF. Although the incubation time of 3h for these ex vivo studies was
shorter than the 24h of the in vivo experiments, it is unlikely that the shorter time frame
contributed to the fact that LXA4 did not augment CD64 expression. This is because
CD64 expression can clearly be enhanced in the time period used, as can be seen in
Figure 5 where neutrophils taken 1h after CLP had substantially greater CD64 expression
compared to neutrophils taken from control mice. These results would argue that the
conditions allowed enough time for there to be an increase in CD64 expression.
Apart from increasing peripheral blood neutrophil phagocytic ability, LXA4
reversed the decline in blood apoptosis commonly found in sepsis and did not affect
PMA stimulated superoxide generation. These results confirm previous work by us that
LXA4 increases neutrophil phagocytic activity and restores apoptosis activity without
excessive free radical production in CLP rats31.
P. aeruginosa is a virulent bacterial strain which causes various infections that
can result in sepsis especially in immunocompromised individuals70. The coordinated
behavior for colonization of higher organisms and virulence of P. aeruginosa is mediated
by binding of 3-oxo-C12 HSL to its native QS receptor, the bacterial transcription factor
LasR. Through this receptor signaling mechanism, P. aeruginosa bacteria coordinate the
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gene expression and release of virulence factors such as exoproteases, siderophores,
exotoxins and secondary metabolites42,44,71-74). In addition, biofilm formation is also
coordinated through this mechanism42,43. Apart from coordinating signals between
bacteria, 3-oxo-C12 HSL activates the hosts’ immune system through stimulation of Tcell production of interferon-gamma (IFN-g) in resting cells75. On the other hand, if
macrophages are co-stimulated with bacterial endotoxin, 3-oxo-C12 HSL increases
production of IL-10, an anti-inflammatory cytokine76 which has been shown to reduce
neutrophil phagocytic ability. These results strongly suggest that 3-oxo-C12 HSL is not
only an important mediator of bacterial virulence by stimulating the expression and
release of virulence factors but can also modulate host, immune responses. Our results
here add to this intriguing inter-kingdom chemical communication crosstalk by
demonstrating that LXA4 with primary activity in the resolution of inflammatory
signaling in the host inhibits the activity of a bacterial QS receptor, LasR, and decreases
the expression of virulence factors in this bacteria. The potency of this inhibition by
LXA4 as evaluated by comparison of IC50 values is several orders of magnitude greater
than any reported LasR antagonist77, and occurs at physiologically relevant
concentrations of LXA4 64. Interestingly, not only is LXA4 an antagonist but it also has
partial agonist activity against LasR (Figure 8b). This property is particularly intriguing
because there is very little structural similarity between LXA4 and a known antagonist,
Br-HSL (Figure 8a) or the endogenous agonist 3-oxo-C12 HSL. The results suggest that
LXA4 acts as a partial agonist and a competitive antagonist at the LasR binding site.
Investigation of related lipid mediators to examine the specificity of LXA 4 for LasR is a
subject of current study.

200

Pyocyanin is an exotoxin produced by P. aeruginosa. It is one of many virulence
factors regulated by quorum sensing pathways and the release of pyocyanin is completely
necessary for P.aeruginosa lung infections78. It is therefore a good marker of P.
aeruginosa virulence. In vitro studies have shown that pyocyanin inhibits cell respiration
and disrupts calcium homeostasis79. Our results show that LXA4 reduced pyocyanin
release from P. aeruginosa at concentrations of 1 – 5 nM LXA4. Taken together with our
results showing that LXA4 inhibits the activity of expression of pyocyanin mediated by
the QS receptor LasR, these observations strongly suggest that LXA4 at physiologically
relevant concentrations can reduce P. aeruginosa virulence.
It is noteworthy that there was a concentration-dependent effect of LXA4 on
pyocyanin release until the highest concentration of LXA4 (8 nM). This bell shaped curve
is characteristic and consistent of previous reports showing that LXA4 effects stop at
higher concentrations56,57. This effect may be due to the partial agonist activity of LXA4
on LasR at higher concentrations of this ligand or could result from potential interactions
with cellular targets in P. aeruginosa in addition to LasR.
Importantly, P. aeruginosa has been reported to possess a secretable 15lipoxygenase enzyme which has been demonstrated to convert arachidonic acid to 15hydroxyeicosatetraenoic acid (15-HETE)80. This would suggest that when P. aeruginosa
is in the vicinity of host neutrophils (which possess the 5-lipoxygenase enzyme),
transcellular biosynthesis of LXA4 can occur. Taken together with our studies, hostbacteria cross-talk may occur to control virulence.
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Experimental Section
All experiments were performed in adherence to protocols approved by the
Institutional Animal Care and Use Committee of Rowan University and strictly complied
with the National Institutes of Health guidelines on the use of experimental animals.
Synthesis of LXA4
LXA4 was prepared synthetically by previously published methods47. The purity
of the compound was measured by HPLC-Mass Spectrometry and determined to be >
98% and 1 mg was dissolved in 500 ml sterile saline on days of experiment.
CLP-sepsis model:
CLP was performed on male CD1 mice (25 – 30g) using modified methods as
previously published (29,30,48). On day of surgery, mice were anesthetized with 2.5%
isofluorane (with oxygen). A 1-cm-long midline incision was made in the abdomen to
expose the cecum. The distal half of the cecum was ligated with 3.0 surgical silk. Using
a 21-gauge needle, the cecum was punctured twice, through and through. A small
amount of fecal matter was massaged out of the cecum through these holes, to ensure
patency of the punctures. The cecum was placed back into the abdomen, which was then
closed in 2 layers. For sham controls, ceca were isolated but not ligated or punctured.
Saline (4 ml/100g; s.c.) was injected to replace any fluids lost during surgery. 1h after
surgery, CLP mice were anesthetized and injected with LXA4 (7 mg/kg), or saline
vehicle, intravenously via the tail vein. This concentration of LXA4 was derived from
published in vivo work in rodents 29,30,49.
The CLP model is widely regarded as the gold standard to study sepsis because it
can be manipulated to different levels of severity and demonstrates bacteremia, a pro-
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inflammatory phase and an immunosuppressive phase 5,7,48.
Isolation of blood leukocytes.
After 24h, mice were anesthetized with ketamine/xylazine (50/10 mg/kg, i.p.). 1
mL of whole blood was drawn by cardiac puncture into 0.05 M EDTA (final
concentration). Blood was lysed using RBC lysis buffer and filtered through a 100 m
cell strainer. Lysed blood was centrifuged (500 x g, 5 min, room temperature), cells were
resuspended in 2 mL of PBS/10% fetal calf serum kept on ice and total cell counts (gated
at > 7 m), were performed (Beckman Coulter counter Z4; Brea, CA, USA).
Bacterial load
1:10 serial dilutions of blood were made and aseptically spread on tryptic soy agar
plates (Sigma-Aldrich; St. Louis, MO, USA) to measure aerobic bacteria growth. The
plates were incubated overnight at 370C. At the end of the incubation period, colony
forming units (CFU) were counted by operators blind to the treatment groups.
Neutrophil free radical production and apoptosis assays
To determine effects of LXA4 on neutrophil free radical production during sepsis,
we performed dihydrorhodamine 123 (DHR123) flow cytometry assays. Initially, 0.5 g
of phycoerythrin (PE) labeled anti-mouse granulocyte antibody, Gr-1 (Biolegend, San
Diego, CA, USA), was added to 100 l of total leukocytes from blood. Debris was gated
out according to their forward and side scatter parameters. The remaining non-debris
population was designated as total leukocyte population. Neutrophils were initially
identified by forward and side scatter parameters (low forward, high side scatter),
followed by Gr-1 surface immunostaining for flow cytometry. Results are reported as Gr1+ cells derived from Gr-1+ cells gated from total leukocyte population. The Gr-1
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antibody (RB6-8C5 clone) has high affinity for Ly6G and low affinity for Ly6C
(manufacturer’s details). Furthermore, the epitope recognized by this Gr-1 Ab overlapped
with Ly6G but not with Ly6C and has been used as a blood neutrophil marker (49).
To determine the appropriate voltage for cells positive for rhodamine, total
leukocytes (1x106/mL) were incubated with 1 M phorbol 12-myristate 13-acetate
(PMA; Sigma, St, MO) at 370C for 15 min, followed by addition of DHR123 (Invitrogen,
Grand Island NY, USA)(5 M), at 370C for 5 min. The reaction was stopped by washing
cells twice with ice cold PBS (500xg, 3 min). Cells from sham, CLP, CLP+LXA4 mice
were stained with DHR123 only (370C, 5 min), Cells undergoing apoptosis and/or
necrosis were determined by staining with Annexin V (4 ml/sample) as recommended by
manufacturer (Biolegend, San Diego, CA, USA), while non-viable/necrotic cells were
detected with 7-amino-actinomycin D (7AAD; Biolegend, San Diego, CA, USA).
Positive Annexin V+ gating was standardized by incubating total leukocytes from each
experimental group with staurosporine (1 M, 370C, 5% CO2, 3h). All samples were
analyzed within 1h of adding Annexin V. In all assays, 10,000 events were collected in
total leukocyte population for each sample using an Accuri C6 flow cytometer (BD
Biosciences; Franklin Lakes, NJ, USA). All assays for determination of neutrophil free
radical and apoptosis were performed in duplicate for each animal and an average for
each parameter was determined for each individual animal.
Neutrophil Phagocytic ability
E. coli bioparticles (pHrodo; Invitrogen, Grand, Island, NY, USA) were
opsonized with E. coli opsonizing reagent for 1h at 370C (1:1 ratio). pHrodo bioparticles
were washed twice (1200 x g, 15 min) to remove any unbound IgGs.
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Opsonized

bioparticles were added to unlabeled total leukocytes from peritoneum and blood (3:1
ratio, bioparticles to leukocytes). Incubations (1h, 370C; 1h, on ice) were stopped by
washing with ice cold PBS twice. Three different time points (30, 60 and 90 min) were
carried out to determine the optimal incubation period for phagocytosis assay. It was
determined that 60 min was the optimum incubation time. Cells that internalized E. coli
were separated from cells that did not internalize E. coli by comparing voltage intensities
between samples placed on ice (negative control) and 370C. Samples were resuspended
and fixed with 0.4% paraformaldehyde and analyzed by flow cytometry the following
day. Immunostaining of Gr-1, FcgRI (CD64) and FcgRIII/II (CD16/32) were performed
after the phagocytosis assays as described above. Similar to free radical and apoptosis,
phagocytosis assays were performed in duplicate for each individual mouse and an
average of the duplicates were calculated. The phagocytic ability is expressed as
phagocytic index. Mean number of E. coli ingested by neutrophils containing E.coli =
mean fluorescence intensity. Therefore
Phagocytic index = % neutrophils ingesting at least 1 E. coli cell X mean florescence
intensity
In separate studies, 8 mg of CD64 blocking Ab or isotype antibody controls was
incubated for 1h with cells isolated from CLP + LXA4 mice prior to phagocytosis assays.
Ex vivo experiments
1h after performing CLP or sham surgery, total leukocytes from blood were
processed according to methods mentioned above. For ex vivo studies, total leukocytes
(105 cells) were suspended in 1 ml RPMI media. Either LXA4 (1, 10 nM) or PBS were
added and the cells incubated at 370C, 5% CO2 for 3h. To confirm the specificity of
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LXA4 actions, a specific LXA4 receptor blocker (50 mM WRW4; Tocris, Loughborough,
UK) was incubated together with cells prior to phagocytosis assays. Reactions were
stopped by adding ice cold PBS/2% fetal calf serum, followed by two washes (500 x g,
room temperature, 4 min). Samples were kept on ice before performing assays in
duplicate to measure phagocytic index as described above for in vivo studies. Cells were
then stained for Gr-1 and CD64. All assays were performed in duplicate and the average
of the duplicates calculated.
Pyocyanin analysis
Overnight P. aeruginosa PA-14 cultures were prepared in cation-adjusted
Mueller-Hinton broth at 37°C with shaking at 300 rpm. The overnight culture was diluted
100 fold into the same medium with the appropriate compounds. The positive control for
pyocyanin included DMSO at the highest concentration used in the assay. LXA4 was
added at 8 nM, 5 nM, 1 nM, and 0.2 nM. All solutions were prepared in duplicates and
were incubated at 37°C with shaking at 300 rpm for 36h. For High Performance Liquid
Chromatography Mass Spectrometry Mass Spectrometry (HPLC-MS-MS) quantification,
1 mL from each overnight culture was transferred into a 2 mL microcentrifuge tubes and
centrifuged at 12,000 X g for 15 min at 21°C. Using a syringe, 500 µL of the cell-free
supernatant was removed and transferred into new tubes. Chloroform (400 µL) was
added to each tube and then centrifuged at 12,000 x g for 1 min. A portion of the bottom
organic layer (200 uL) was transferred into a vial for Ultra Performance Liquid
Chromatography Mass Spectrometry Mass Spectrometry (UPLC-MS-MS) analysis. The
samples were subjected to HPLC separation through an in-line Waters 2795 Separations
Module on a BETASIL 5 mm Phenyl-Hexyl HPLC column (Thermo
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Waltham, MA, USA) using a linear gradient of ACN/H2O (0.1% formic acid modified,
5% to 95% ACN) and were analyzed in positive ion mode on a Waters Micromass
Quattro MS-MS by evaluating the TIC for the presence of pyocyanin molecular ion at
m/z 211.28. The identity of pyocyanin was further confirmed by monitoring the presence
of a characteristic fragmentation peak at m/z 168.33. The concentration of pyocyanin was
determined by recording the TIC for m/z 211.28 of triplicate injections of the duplicate
samples by comparison to an external calibration curve generated using pure pyocyanin
(Aldrich, St. Louis, MO, USA).
LasR Reporter Strain Bioassay
The LasR reporter strain bioassay was performed as described previously (43)
with modifications. The reporter strain was kindly provided by Bonnie L. Bassler
(Princeton University). This E. coli strain was grown overnight at 37oC in Luria broth
(LB) (Fisher Scientific) maintained with 100 µg/mL ampicillin and 50 µg/mL of
kanamycin. The overnight culture was subcultured 1:40 for bioassay analysis. For agonist
assays compounds were added to the diluted overnight reporter strain in 96-well black
microplates with clear bottoms (Corning) at the starting concentrations described and
titrated by serial dilution. Plates were incubated with shaking at 37oC for 4-6h and were
evaluated for fluorescence (ex485/em538) and absorbance (A600) using a Molecular
Devices SpectraMax M5 microplate reader. The native LasR agonist, N-3-oxododecanoyl-L-homoseriene lactone was utilized as the positive control for this assay. For
antagonism assays, the native LasR agonist, 3-oxo-C12 HSL was employed at a constant
concentration of 50 nM. The previously described antagonist, (S)-2-(4-bromophenyl)-N(2-oxotetrahydrofuran-3-yl) acetamide (Br-HSL) was used as the positive control for
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antagonism (50). LXA4 or control compounds were added to the diluted overnight
reporter strain containing 3-oxo-C12 HSL, titrated by serial dilution and analyzed as
described for the agonist assay.
Statistical analyses:
One way analysis of variance (ANOVA) was used to analyze all data with more
than 2 groups, using GraphPad Prism 6 software. Differences between groups were then
ascertained using Newman-Keuls test of significance. In cases when there were only 2
groups, significance was analyzed using the unpaired t-test. For bacteria load, the MannWhitney U test for non-parametric data was used. In ex vivo studies, changes were
expressed as percentage increase from controls samples incubated without LXA4. Doseresponse curves for the LasR-reporter strain studies were fit to the data using standard
nonlinear regression data fitting settings in GraphPad Prism 6. Differences between
groups are considered significant at p < 0.05.
Conclusion
This study provides evidence that LXA4 increases host response against infection
by augmenting neutrophil CD64 mediated phagocytic ability as well as reducing bacterial
virulence. This novel dual property of LXA4 working on both host defense and pathogen
virulence warrants further investigation. Future studies on LXA4 and related proresolving mediators may lead to discovery of a new class of antimicrobial which
upregulates host defense and simultaneously reduces bacterial virulence.
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Figure 22. LXA4 inhibits the
expression of P. aeruginosa
virulence factor, pyocyanin.
Pyocyanin concentrations were
determined by integration of the LCMS total ion chromato- gram (m/z,
211.2) on the basis of the correlation
with a standard curve that was
prepared by using pure pyocyanin.
The data are presented as means 6 SD
of n = 3. *P , 0.05; **P , 0.01.

Figure 23. A) LXA4 inhibits the
LasR QS receptor. Inhibition
values determined employing
the green fluorescent protein
(GFP)–based LasR antagonist
bioassay. Inhibition of LasR at
the compound concentrations
indicated is shown as means 6
SD of n = 3. B) Antagonism
dose-response curve for LXA4
and Br-HSL (known LasR
antagonist) in the presence of 50
nM of the native LasR agonist,
3-oxo-C12 HSL. OD, optical
density. Data points are means
of n=3.**P,0.01.
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Figure 24. A) Competition binding
assay for LXA4 inhibition of LasR.
The native LasR agonist, 3-oxo-C12
HSL, was titrated against fixed
concentrations of LXA4. Increasing
values for the titration of the native
agonist in the presence of increasing
concentrations of inhibitor is
consistent with LXA4 acting as a
reversible antagonist of this
receptor. B) LasR agonist as- says
were performed by using LXA4, 3oxo-C12 HSL, and DMSO. LXA4 is
a partial agonist of LasR in P.
aeruginosa in which maximum
response is less than the maximum
response of the endogenous ligand,
3-oxo-C12 HSL. GFP, green
fluores- cent protein; OD, optical
density. All data points are means 6
SD of n = 3.
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